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Seen as one of the major causes of death worldwide, Cancer requires the development of 
effective treatments in order to combat the disease. However, pharmaceutical companies are 
faced by the challenge of finding and developing a suitable compound that can override the 
barriers of the human body and operate effectively in its pharmacological properties.  
The research conducted in this investigation looks at a naturally occurring compound, 
Dibenzoyl methane (DBM), its derivatives, and a few additional synthesised compounds with 
similar chemical properties and their unique activities demonstrated. DBM and its derivatives 
are classified as β-diketones and were synthesised using two different chemical schemes; the 
Baker-Venkataraman rearrangement and the Claisen acylation. 
In comparison to this, a recently discovered synthetic class of compounds, N-benzoyl-N’-
phenylurea and derivatives were also studied during the period of this investigation. The 
cytotoxicity of the drug candidates was determined on live mammalian cell lines including 
HepG2, HeLa and HCT 116 amongst a few supplementary cell lines using the MTT assay. In 
addition since the final stage of a potential drug compound is associated with the mechanisms 
of a human body, pharmacological factors such as stability within plasma and metabolic 
stability were measured. These are responsible for measuring the degradation of the 
compound over time and looking at the ability of the liver to remove the administered drug 
respectively. The data was collected and appropriately converted to be plotted and analysed 
to assess the efficacy of the drug candidates as potential anti-cancer agents 
 




µl    microlitre(s) 
µm    micrometre(s) 
µM    micromolar 
µs    microsecond(s) 
13CNMR    Carbon-13 nuclear magnetic resonance 
1HNMR    Proton nuclear magnetic resonance 
Aq     Aqueous 
CH3CN    Acetonitrile 
COOH     Carboxylic Acid 
CuAAC    Copper (I)-catalyzed alkyne-azide cycloaddition 
DCM     Dichloromethane 
dd    double doublet 
DMF    Dimethylformamide  
DMSO     Dimethyl Sulfoxide 
DMSO    Dimethylsulfoxide 
DNA     Deoxyribonucleic Acid 
14 | P a g e  
 
EDTA    ethylenediaminetetraacetic acid 
EG    ethylene glycol 
Eq     Equivalence 
eq.    equivalent(s) 
et al.    from Latin Et alia (and others) 
Et2O    Diethyl ether 
EtOAc     Ethyl Acetate 
EtOH    ethanol 
g    gram(s) 
GC    gas chromatography 
h    hours(s) 
H2SO4    sulphuric acid 
HCL     Hydrochloric Acid 
HeLa    immortal cervical cancer cells derived from Henrietta lacks 
HPLC     High-performance liquid chromatography 
Hz    Hertz  
IC    internal conversion  
IC50     half maximum inhibitory concentration 
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in vacuo   lat. “in empty space” (under a vacuum) 
in vitro    lat. “in glass” 
in vivo    lat. “within the living” 
IR     Infrared Spectroscopy 
J    coupling constant (Hz) 
LCMS     Liquid chromatography-mass spectrometry 
Lit.    in the literature 
logP    octanol-water partition coefficient 
M    molar  
m    multiplet 
m.p.    melting point 
MDR    multidrug resistance 
MeCN    acetonitrile  
MeOH    methanol  
mg    milligram(s) 
MgSO4    Magnesium Sulfate 
MHz    megahertz 
min    minute(s) 
16 | P a g e  
 
mL     Millilitre 
ml    millilitre(s) 
mm    millimetre(s) 
mM    millimolar 
mol    mole(s) 
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mW    milliwatt(s) 
NADH    nicotinamide adenine dinucleotide 
NIST     National Institute of Standards and Technology 
nm    nanometer(s) (10-9m) 
nM    nanomolar (10-9M) 
NMR     Nuclear magnetic resonance  
OMe    methoxy group (-OCH3) 
PBS    phosphate buffer-solution 
Pet.    Petroleum ether 
Ph    phenyl   
ppm    part per million  
Rf    retention factor (in TLC) 
17 | P a g e  
 
RNA     Ribonucleic Acid 
ROS    reactive oxygen species 
rt     room temperature (approx. 22oC) 
s     singlet 
sat.    saturated 
SiO2    silica (silicon dioxide) 
STORM   stochastic optical reconstruction microscopy  
t-     tertiary 
t     triplet 
THF    tetrahydrofuran 
TLC     Thin-layer Chromatography 
TMS    tetramethyl silane 
UV     Ultra-violet light 
v/v     volume/volume ratio 
W     Watts 
δ    chemical shift in NMR (usually given in ppm) 
λ    wavelength (nm) 
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1.  Introduction 
1.1     Cancer 
1.1.1  What is cancer? 
“Everything is poisonous, and nothing is harmless. The dose (amount) alone defines whether 
something isn't poison”i Paracelsus, 1493-1541. 
The term cancer, present in every corner of the world, be it rich or poor, is used to describe a 
disease which has become a thorn to mankind. Here, cancer is defined whereby cells, 
classified as abnormal, divide uncontrollably and hence invade other healthy tissues within 
the body. Through systems readily available in the body such as blood and lymph, these newly 
formed cancer cells can spread in the body, affecting the body so much that it will ultimately 
lead to death. 
1.1.2  Data Statistics 
 
Cancer is one of the leading causes of mortality in the developing countries and throughout 
the world. In the United States of America. Cancer is currently the 2nd leading cause of death 
after heart disease and is predicted over the next few years to surpass heart disease (Siegel, 
Miller, & Jemal, 2015). In addition, there are more than 360,000 new cases of cancer reported 
in the UK every year and an estimated 14 million worldwide. In respect of the preceding 
decade, the incidence rate for cancer has increased by 7% and is projected to increase by a 
further 2% over the next two decades across the globe, resulting in 23.6 Million new cases of 
cancer globally each year by 2030. There are more than 22 types of cancers (Marshall et al., 
2016), thus regardless of numerous efforts, the disease still demands improved treatments 
(Liu, Miyoshi, & Nakamura, 2007). 
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Every year there are 164,000 cancer deaths recorded in the UK out of which 88,200 are 
accounted for by males, but on a global scale there are 8.2 million deaths recorded due to 
cancer. More than a quarter of the deaths occurring in the UK are due to cancer of kinds such 
as breast, prostate and lung. However, bowel cancer equates to half of those deaths, thus 
being the dominating type, as informed by Gundem and colleagues in 2015. There is no offset 
age for cancer as it can be acquired at any age, nevertheless, Bassily and colleagues (2010) 
distinguished that reports show tendencies of escalation as of the age of 55 and established 
that over a third of all cancer cases in the UK are from diagnoses of individuals aged over 75 
years. The cellular natural ageing process and a prolonged time of accrued mutations are the 
main causes of this increase. 
1.2  Types of Cancer 
 
There are numerous kinds of cancer that affect cells all over the body. The different types of 
cancer can be classified according to the type of cell or tissue where the cancer originates. 
There are six major types of cancer (Danø et al., 2005). 
1.2.1  Blastoma  
This type of cancer is derived from embryonic tissue and most commonly found in children 
(Indolfi et al., 2007). 
1.2.2 Carcinoma  
This is the most common type of cancer. Carcinoma starts in epithelial cells and cells that 
make up the skin or the tissue lining organs, like the liver or kidneys. Like other types 
of cancer, carcinomas are abnormal cells that divide without control. They can spread to 
other parts of the body, but do not always do so. "Carcinoma in situ" remains in the cells 
where it started. Common forms are breast, lung and colon (Pannathur et al., 2013). 
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1.2.3 Sarcoma 
This is a rare kind of cancer. These are tumours of the connective tissue. All sarcomas 
initiate from mesenchymal cells from the bone marrow. Examples of inclined tissues 
include cartilage, bone, muscle and fat (Danø et al., 2005) (Miller & Mihm, 2006).  
1.2.4 Melanoma 
This is a type of skin cancer. Melanoma initiates in skin cells that are positioned in the 
deep layer of the epidermis amid the layer of the basal cells called melanocytes. These 
cells make a pigment called melanin, this is responsible for giving the skin its natural colour 
but also delivers protection to the body from ultraviolet radiation from the sun (Miller & 
Mihm, 2006).   
1.2.5 Lymphoma  
This cancer starts in the lymph glands or other glands belonging to the lymphatic system. 
Though there are many different types of lymphoma, there are 2 main ones 1). Hodgkin 
lymphoma – cancer of a type of white blood cell called lymphocytes. This type of 
lymphoma contains cells called Reed Sternberg cells. Treatment for this type of lymphoma 
is very different to other lymphomas (Küppers, Engert & Hansmann, 2012). 2). Non-
Hodgkin Lymphoma (NHL) – is a cancer of the lymphatic system. There are over 60 
different types of NHL (Nossal, 1994).  
1.2.6 Leukaemia  
This cancer starts in blood, forming tissue which is usually the bone marrow. This cancer 
leads to the over-production of abnormal white blood cells, this affects the part of the 
immune system, that protects the body against infection. Leukaemia can be classified by 
the type of white cell that is affected (myeloid or lymphatic) and by the way this disease 
progresses (acute or chronic) (Pui, Robison & Look, 2008). 
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1.3  Causes of Cancer 
Cancer is a risk to most multicellular organisms, and inherent defence mechanisms have 
established throughout time in the pursuit to stop or prevent the occurrence and progression 
of cancer. Cell cycle regulation, programmed cell death, immune responses, replicative aging 
limits, DNA mismatch repair, and the differentiation of cells and architecture of varied tissues 
are processes that cause the natural resistance to cancer (Hochberg & Noble, 2017). There 
are large variety of influences that play a role in the development of cancer. These can be in 
the form of genetic predisposition, age and lifestyle categorised as host factors, lengthy 
infection, the agents one is exposed to in their daily lives and finally environmental factors 
one resides in.  As cancer cannot be classified as a single disease triggered and caused by a 
single factor, it becomes a challenge to single out the cause of development in individual cases 
(Danaei et al., 2005).   
1.3.1 Environmental Factors 
 
There are multiple external environmental factors combined with genetic mutations that can 
lead to and cause human cancers, thus meaning that cancers originate from both 
environmental and genetic influences. Mutations of certain genes can cause cancer, and some 
of the mutations are due to natural occurrences amidst the process of DNA replication during 
cell division. Whereas, others are a result of environmental exposures that damage the DNA. 
These exposures include chemicals in tobacco smoke or radiation found in ultraviolet rays 
from the Sun (Holick, 2008).  
There have been links established between the consumption of alcohol and exposure to 
pesticides with likes of dichlorodiphenyltrichloroethane (DDT) and 
dichlorodiphenyldichloroethylene (DDE) and the development of breast cancer. Consumption 
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of red meat and folic acid intake have been linked to a rise in colorectal cancer and UV 
exposure and use of photosensitising drugs have been heavily linked with melanoma 
incidences (Chan et al., 2011).  Studies have also shown that 97% of all cancers are caused by 
environmental and man-made influences such as red meat, tobacco, chemicals and 
environmental pollutants including radiation spills, exhaust fumes and the burning of fossil 
fuels (Parkin, Boyd & Walker, 2011). The largest contributor and cause of cancer is smoking 
in the UK, with a figure equating to 15%. 
1.3.2 Infection 
 
Infection has also been associated with cancer development, being granted an approximate 
figure of 17.8% figure of all cancer incidences being accounted for by some type of infection. 
Of this figure 12.1% are attributed due to viral infections. Infections in the form of bacterial, 
parasitic and viral have all been linked to tumour occurrence due to their triggering of 
prolonged and chronic inflammation, which are ideal conditions needed for the proliferation 
of neoplastic cells (Collins, Hogan & Winter, 2011). 
When an infection, such as hepatitis C, attacks the body, then the immune system will thrive 
to eliminate and destroy the infection. This is performed by prompting localised, acute 
inflammation which only persists for a brief period. If this is not successful, prolonged acute 
inflammation may occur, this is then what causes the optimum conditions promoting 
neoplasms (Danaei et al., 2005). These conditions also heighten the generation of large 
numbers of inflammation causing cells, these release cytokines, nitric oxide, isoforms of nitric 
oxide synthase and reactive species that are derivatives of nitric oxide. All these excretions 
possess the ability to cause direct damage to DNA and impact proliferation and 
neoangiogenesis (Collins, Hogan & Winter, 2011).  
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With regards to bacterial infections, there are two non-specific mechanisms that are linked 
by belief to carcinogenesis; inflammation, witnessed in the Helicobacter pylori (H. pylori) 
infection, and bacterial metabolism leading to the generation of mutagenic compounds 
(Graham, 2000).  
H. pylori present as a gram-negative rod-shaped bacterium, is positioned in the mucus layer, 
situated amid the stomach and the gastric epithelium and has demonstrated to not migrate 
or invade neighbouring tissues such as penetrating the basement membrane.  H. pylori is 
classified as a group 1 carcinogen and highlights a direct link to cancer formation. This is due 
to H. pylori infection triggering chronic superficial gastritis which then causes an increase in 
adenocarcinoma incidence 2-fold. In addition, statistics dictate that 3.5% of chronic 
superficial gastric victims will then progress to develop chronic atrophic gastritis instigating 
an increase in adenocarcinoma incidence a further 9-fold (Graham, 2000) (Polk & Peek, 2010). 
 1.3.3 Genetics 
 
Genetics also establish a crucial role in carcinogens with mutations in genetic material taking 
place both naturally and being passed down genetically. While naturally occurring, mutations 
are very challenging to predict and treat, as they are unintentional and often associated with 
the exposure to environmental stimuli such as radiation or mutagenic agents. However, it is 
possible to act preventively if the mutation is inherited (Hong et al., 2013). A prime example 
of inherited defects includes the BRCA1 and BRCA2 tumour suppressor genes, these are 
significant in the preservation of genomic stability by enabling the homologous 
recombination (HR) restoration of DNA double strand breaks, proliferation control and 
growth regulation. Mutations in the BRCA1 and BRCA2 genes are directly associated with an 
increased risk of developing breast cancer and ovarian cancers. Nevertheless, for 
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tumorigenesis to happen, the incidence of two events is vital; the first is that the patient must 
have acquired the mutated BRCA allele, and the second is that the patience must undertake 
somatic inactivation of the second BRCA allele (Moyer, 2014). 
1.4  The Cell 
 
Albeit the human body is a complex system which takes specific depth to understand, the 
foundation is purely based upon a small component, the cell. The cell predominantly is the 
unit of life within the human body, and all cancers begin within this component, the cell. A 
small structural unit consisting of biological and functional information, the cell, which is often 
described as a building block of life, can replicate independently hence make an abundant 
amount of copies of themselves. As well as providing structure, energy and carrying out 
localised specialized function, contained within a cell can be found the hereditary material 
such as DNA, RNA and chromosomes.  
1.4.1 Cell Division 
 
In order to maintain and grow, cells within the human body undergo a process in which a 
parent cell will divide into two or more daughter cells. This process is called Cell Division and 
usually occurs as part of the mammalian cell cycle. 
In order to form new, fully functioning cells, both normal and cancer cells must undergo a 
series of phases, 5 to be specific. This chain of events is given the term, the cell cycle, and 
shown in schematic literature annotated using the characters G0, G1,S,G2,M which describe 
each phase. The cell cycle is a set of events which result in cell growth and division into two 
daughter cells (Huang et al., 2013). After an initial reproduction stage, the newly formed cells, 
2 to be precise, are identical to each other. When a new pair of cells is required by the body, 
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the 2 cells formed from the initial cell can undergo the cell cycle, in order to produce more 
cells. The way the phases work is briefly outlined below, with all 5 phases mentioned. 
1.4.2 G0 Phase 
Also called the ‘Resting stage’ the cell has not yet initialised the splitting process. A cell will 
spend most of its maturing life within this stage, with the length of this phase lasting from 
anywhere between a few hours to a few years for specific cells. Upon receiving a signal, the 
cell will progress to the G1 phase, where it will undergo reproduction. 
1.4.3 G1 Phase  
Lasting around a period of between 18 to 30 hours, the cell in this phase starts to produce 
more protein, thus increasing its mass in size, forming cells of a normal size. Preparation for 
DNA replication occurs in this stage (Huang et al., 2013). 
1.4.4 S Phase 
Containing the genetic information (DNA), the chromosomes undergo replication, whereby 
matching DNA strands are present as a template in both new cells formed. Named the S 
phase, the duration for this stage is between 18 to 20 hours. 
1.4.5 G2 Phase 
After the DNA is defiantly checked, the cell will now start a process of splitting the cell into 2 
different cells. This can take anywhere from between 2 to 10 hours. 
1.4.6 M Phase 
Given the term the ‘M Phase’, this is the final stage where Mitosis takes place. Lasting a very 
small amount of time, in comparison to the other phases, this process takes around 30 to 60 
minutes. During this phase, the cell essentially splits itself into 2 new different cells, which are 
identical to each other. Nuclear and cytoplasmic division also occurs. 
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1.4.5 Mutations 
Though many variations/mutations of cancer are present there is one simple mechanism 
followed by all types. This phenomenon is dictated when the normal cycle of old cells dividing 
and being replaced by new ones is taken over to an uncontrollable rate of abnormal cell 
growth, invading and spreading to various locations sites in the human body. When a 
mutation arises, the process of apoptosis, defined by Chiu and colleagues in 2013, as a 
programmed cell death, which controls the development and homeostasis of multicellular 
organisms by the elimination of damaged, age or mutated cells for the old cell does not occur, 
thus leading to a great influx of new cells forming, an amount that the body does not require. 
The formation of extra cells leads onto produce the mass production of cells for masses of 
tissue that develop into a tumour (Ikediobi et al., 2006).  
However, tumours which exist in the body are not all cancerous, there are some cancers that 
do not involve the formation of a tumour such as leukaemia. Defined as non-cancerous, 
benign tumours are often removed in several cases, and do not return. The cells which are 
involved with a benign tumour do not spread to different parts of the body. On the other 
hand, described as cancerous, malignant tumours do spread throughout the body. This is 
mediated through a process called metastasis, where the cells invade nearby tissues and are 
often circulated around the body (Rahbar et al., 2013) (Tward et al., 2007).  
During the process of cell division, there are a variety of processes that can occur either 
separately or as a collection which identify whether there is any damage to DNA that 
necessitates correction (Finn, 2008). However, a cell that has suffered and gathered a large 
amount of DNA damage or a cell that no longer possesses the capability to effectively repair 
the damage, is able to enter one of the following three possible states: 
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i. Senescence; this state will cause the cell to become dormant. 
This phenomenon is also known as the ‘Hayflick limit’ and was explained by Hayflick and 
Moorhead (1961) as one where a normal cell can no longer divide. In an investigation that 
was conducted, it was discovered that in normal human fibroblasts in culture, achieve 
approximately 50 cell population doublings at maximum before becoming senescent. 
Hayflick discovered that all cultured cells are mortal, and the only immortal cultured cells 
are the cancer cells. 
ii. Apoptosis; this state crusades programmed cell death 
Apoptosis advances as a speedy and permanent process to proficiently eliminate the cells 
that are dysfunctional (Letai, 2008). A trademark of cancer is the ability of malignant cells 
to avoid apoptosis (Hanahan & Weinberg 2011). Cancer cells can reveal many features 
that would encourage apoptosis in healthy functioning cells. Examples include that they 
disturb certain stages of a cell cycle that aid in the enduring of cytotoxic agents’ exposure. 
Due to these disruptions, cancer cells hold the tendency to subsist (Letai, 2008). Therefore, 
apoptosis is an important barrier to growing cancer, avoiding apoptosis is a crucial 
fragment to the development of tumour (Cory & Adams, 2005) & (Plati et al., 2011).  
iii. Cancerous Tumours; this state emerges due to unregulated cell division.  
This when cancerous cells have the capability to divide without suitable external signals 
and do not exhibit contact inhibition. This leads to the continuous dividing of the 
cancerous cells in the presence of genetic damage. Finally, this continuous division of 
genetically damaged cells can lead to the formation of tumours (Castonguay et al., 2017).  
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In the instance where the cell enters the third state and becomes a tumour, the mutation is 
passed on the next cell during the process of cell division as shown in Figure1. (Shirzadfar, 













The Human body is made up of approximately 37.2 trillion human cells. These cells perform 
as the body’s foundation of the building blocks and have fixed features that permit them to 
endure accurate functioning of tissues, organs and organ systems (Kusmartsev et al., 2008).  
In the initial stages of cell division, the molecular regulatory and biochemical mechanisms in 
cancer cells possess a lot of similarities when compared to those of ‘normal’ cells, hence, they 
Figure 1 A comparison showing the process of cell division between normal and cancerous 
cells as they divide (adapted from (Shirzadfar, Riahi & Ghaziasgar, 2017)) 
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are not recognised as being foreign by the body’s defence system. The immune system is only 
triggered partially, and the growth of the tumour becomes overwhelming for the response to 
be effective. For this very reason, early diagnosis and prompt treatment of cancers are vital 
for the success of anticancer treatment and lasting survival of patients (Pantel, Brakenhoff & 
Brandt, 2008).   
‘Hallmarks of Cancer’ is a term used to describe the specific characteristics which differentiate 
a cancerous cell from a normal one (Fig 2) (Hanahan & Weinberg, 2011). 
 
 
Figure 2 The 10 distinguished Hallmarks of Cancer (adapted from (Hanahan & Weinberg, 2011)) 
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1) Cell shape - Normal human cells come in many shapes and sizes due to their ability to 
adopt and differentiate specialised roles. Unalike cells do not look identical, but, if cells 
were examined of the identical cell type, they will look enormously similar, sustaining 
a uniform shape. Cancer cells on the other hand, are misshapen and look like a chaotic 
assembly of cells, as a selection of shapes and sizes (Bizzarri et al., 2011).  
2) Nucleus - In normal cells the nucleus has a smooth appearance and preserves a uniform, 
spheroidal shape. The nucleus in a cancer cell is misshapen and bulges defined as ‘blebs’ 
can commonly be distinguished in the cells’ nuclear membrane (Barua & Mitragotri, 
2013).  
3) Chromatin - In normal cells, chromatin is fine and evenly distributed but transformed 
into coarse in cancer cells, it is aggregated into irregular clumps that vary in size and 
shape (Bizzarri et al., 2011).  
4) Nucleolus - In cancer cells the nucleolus becomes increasingly enlarged and further 
irregular, they can have multiple nucleoli within the nucleus (Barua & Mitragotri, 2013) 
(Bizzarri et al., 2011). 
5) Blood supply - In normal cells Angiogenesis (development of new blood vessels that 
form from pre-existing vasculature) is a vital process. This occurs during development, 
growth, and wound healing. In the growth of cancer this is implicated, through the 
tumours ability to secrete chemical signals that arouse angiogenesis (Figure 3) (Nishida, 
2006).  









 Normal Cell Cancer cell 
(Images Adapted 
from Cancer 
Research UK 2018) 
  
Cell Shape Uniform Irregular 
Nucleus Spheroid, single nucleus Misshapen, common to have 
multiple nuclei 
Chromatin Fine and evenly distributed Coarse, aggregated 
Figure 3 Showing how Tumours can stimulate neighbouring cells to harvest angiogenesis 
signalling molecules resulting in the formation of new blood vessels to occur (Nishida, 2006). 
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Nucleolus Single, inconspicuous 
nucleolus 
Multiple and enlarged nucleoli 
Cytoplasm Large volume of cytoplasm Small volume of cytoplasm 
Growth Controlled Uncontrolled 
Maturation Mature into specialised cells Remain immature and undifferentiated  
Blood Supply Normal angiogenesis which 
occurs during healing and 
development. 
Tumour induced angiogenesis 
Oxygen Favoured but will undergo 
anaerobic respiration if 
necessary. 
Not needed and favour anaerobic 
respiration 
Location Remain in intended location Can spread to various locations in 
the body (metastasis) 
Figure 4 Selective differences between normal healthy cells and cancerous cells. (adapted 
from (Nishida-Aoki and Ochiya, 2015)) 
 
There are individuals born with a higher susceptibility of acquiring cancer and that is due to 
the genetic predisposition with the inherited mutations that contribute towards the 
formation of cancer (Boffetta & Nyberg, 2003).  
A leading instance is individuals born with BRCA11, BRCA2 and p53 modifications are less able 
in the successful suppression of cancer growth (Vogelstein & Kinzler, 2004). This is because 
these proteins aid in the repair of damaged DNA, hence ensure the stability of each cell’s 
genetic material. The mutation, or alteration of either of those proteins, where the protein 
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product is not made or does not function appropriately, DNA damage may not be restored 
correctly, causing cancer (Abdul, Santo & Hoosein, 2003).  
Various forms of tumours can develop through tissues that are susceptible to malignancies, 
even though all tumours have distinctive features, the underlying mechanisms are similar. 
The healthy and functioning cells present in the human body exist in a multifaceted co-
dependent system that orders their spread. The existing healthy and functioning cells will only 
reproduce with the instructions received from neighbouring cells, this ensures the 
preservation of a suitable tissue size and structure (Dawson & Kouzarides, 2012). Cancerous 
cells on the other hand perform metastasis.  This when they divide very rapidly at an abnormal 
rate, causing a change in structure of tissue along with evading controls on development with 
the potential to spread throughout the body. The deviations that occur in a cell which lead to 
cancer ensue due to widespread of mutations genes within the cell (Lamb et al., 2003). 
Eukaryotic cells those which contain a nucleus also contain genes. These genes are present in 
the nucleus of the cell and comprise of specific sequences of DNA that are arranged as 
chromosomes. Every single of the genes within the nucleus, codes for a specific protein, this 
code determining the order in which the amino acids are joined together. The mutations in 
these genes can consequently cause a change in the functioning or the amount of the protein 
product (Caraglia et al., 2001). Proto-oncogenes (a normal gene that is mutated to become 
an oncogene and is then an active participant towards the contribution to cancer) and anti-
oncogenes (a category of gene that makes tumour suppressor proteins which aids in the 
governing of cell growth) are the two types of genes that determine cancer. In other words, 
proto oncogenes regulate differentiation and cell growth while anti-oncogenes suppress the 
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growth of cells, as explained by Croce in 2008 then further supported by Smith and colleagues 
in 2011. 
1.6  Cancer treatment/s 
Cancer is a disease that has an unpredictable nature, different means of diagnosis are 
considered for a different type of cancer. There are multiple types of treatment in 
combination recommended for certain types of cancer, but this is dependent on the location 
in the body and its severity.  There are three traditional methods to treating cancer and these 
are; surgery, radiotherapy and systemic therapy. These well established and different 
approaches are sometimes applied in combination or even as a separate entity (Wust et al., 
2002). 
1.6.1 Surgery 
One of the cancer treatment approaches is surgery. Cancer surgery is one of the oldest types 
of cancer treatment and is still effective for many cancers today. Despite the advancement 
and alternatives existing in treating tumours, surgical intervention has sustained to be in the 
lead, especially, when other treatment possibilities could not stance as a cure. The concept 
behind this method is that eliminating the affected part would hinder the cancerous cells from 
performing metastasis (Gudmundsson et al., 2009).  Thus, Cancer surgery removes the 
tumour itself and entails removal of the neighbouring tissue during the procedure. There are 
several factors that determine whether surgery is an option, and this includes the type of 
cancer an individual has; the size and stage of cancer, where the cancer is in the body and the 
general health of the patient (Pastan et al., 2007).  
Surgery only treats the part of the body that it is operated on, thus, surgery has the possibility 
of curing cancer that is completely confined to one specific area. It is possible to increase the 
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life expectancy with surgery for individuals with certain type of cancer. This can ultimately 
lead to cure. If, however, the cancer has spread to additional parts of the body, then surgery 
can not cure it. Surgery in combination with chemotherapy or radiotherapy bids an option to 
reduce aggressive intervention and aids in countering microscopic levels of a tumour that 
cannot be removed through surgical means (Paun et al., 2010). 
1.6.2 Radiotherapy 
Radiotherapy also known as radiation therapy is a cancer treatment that involves exposing 
the tumour to high doses of radiation to shrink or ultimately kill them. This therapy includes 
concentrating an ionising radiation medium on the portion affected with cancer or a benign 
tumour (Woodhead et al., 2016). This is done by slowly damaging the cancers DNA to the 
extent beyond repair, stop dividing or die. When damaged cells die, they are broken down 
and removed by the natural processes of the body (Formenti & Demaria, 2013). Radiation can 
be applied on tissue through direct or indirect means. The direct method entails ionising an 
atom by losing an electron from its outer shell, creating a positive charge. Photons of light 
focused on particles also result in emitting high energy radiation. Molecules producing 
radicals is a result of indirect radiation. In both cases, a photon colliding with an atom or 
molecule is skilled at expunging an electron from DNA. This results in damaging the tissue, 
which is the principle underlying radiotherapy (Mayadev et al., 2018). 
Delaney and colleagues in 2005 explain that radiotherapy is not able to destroy cancer 
straight away. It can take a period of days even weeks of treatment before the DNA of the 
cancer cells itself is damaged. This is then followed by cancer cells dying for weeks and months 
after the end of radiotherapy. The type and timing of radiotherapy being administered on the 
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patient is dependent on the type of cancer being targeted and whether the goal of radiation 
is to treat the cancer or ease the symptoms associated.  
When radiotherapy is combined with other treatments for cancer it can be given in the 
following stages; before surgery – this would shrink the size of the cancer for surgical removal 
to be more efficient and the likelihood of the cancer returning would be minimalised. The 
second would be during surgery- so that the cancer is radiated without having to pass the 
radiation through the skin (Bosset et al., 2006). Radiotherapy implemented in this manner is 
called ‘intraoperative radiation’. Through this procedure, doctors can protect neighbouring 
tissue easily from radiation. Finally, the third stage of administration would be after surgery 
– to destroy any cancer cells that remain (Forastiere et al., 2003).  
Radiotherapy is an effective treatment for cancer patients. The Royal college of Radiologists 
(2015) explained that four of ten patients with cancer are treated with radiotherapy. 
Radiotherapy has also proven to be cost effective as it equates to only 5% of the total cost of 
the treatment available to cancer patients (Sharma et al., 2016) (Muirhead et al., 2015). 
1.6.3 Chemotherapy 
Chemotherapy is a term which defines as the use of chemical to treat disease. Chemotherapy 
is circulated through the bloodstream in the body; therefore, it can treat cancer located 
almost anywhere in the body. Hence, this is known as systemic treatment. Chemotherapy 
targets cells for damage as they divide. The nucleus of the cell contains chromosomes which  
are made up of cells. The nucleus is the control centre of the cell. The genes present must be 
copied exactly each time cell division occurs in order to make two new cells as highlighted 
from Figure 5. (Skeel & Khleif, 2011) (Shah et al., 2019).  











Figure 5 shows how Chemotherapy damages the cells inside the nucleus of the cells. Drugs 
depending on their nature will damage cells at the point of splitting, while others when they 
are making copies of genes before the process of splitting. Chemotherapy, on the other hand 
is much less likely to effect cells that are at rest (Skeel et al., 2011) and (Tobis, Hochhauser & 
Souhami, 2010).  
Farber and his peers in 1948 searched for curable measures to harness child acute 
lymphocytic leukaemia, this marked the beginning of chemotherapy. Since then, interests for 
the search and development of drugs and therapies aimed at cancer established rapidly 
(Bowder et al., 2000). The mechanism of chemotherapy drugs or chemical agents destroying 
dividing cells aids to explain why this very traditional approach to cancer treatment also 
causes side effects. However, chemotherapy is often preferred for the specificity towards 
their targets in the cellular environment, an example would include blocking targeted 
Figure 5 The process of cell division. Adapted from Cancer 
Research UK (Skeel et al., 2011) and (Tobis, Hochhauser & 
Souhami, 2010). 
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pathways within the phases of cell cycle. This approach also affects healthy and well-
functioning body tissues where the cells are continuously growing and dividing (Smith & 
Pewett, 2017).  
Chemotherapy can impact hair, bone marrow and skin. These tissues are affected because 
they have dividing cells. However, normal functioning cells can replace or restore the cells 
that are damaged by chemotherapy. Thus, the conflict subsists, as chemotherapy drugs are 
known for their role in attacking DNA in cancerous cells, but subsequently, the toxic effect of 
the drug is a possible threat to the microenvironment (Scharovsky, Mainetti & Rozados, 2009). 
The damage occurred by the healthy cells is not permanent, most side effects disappear once 
the treatment is completed explain Marijnen et al., 2002. However, side effects such as 
sickness and diarrhoea might occur but are most likely to subside once the intake of drugs has 
been stopped (Hickok et al., 2005).  
Moreover, chemotherapy plays a substantial part in gynaecological malignancies amid female 
patients suffering from peritoneal cancer as the epithelial tissue on the ovaries and linings 
that shield the organs in the abdominal cavities are targeted due to cancer (Smith & Pewett, 
2017) (Webber & Friedlander, 2017). 
There are several mediums of administering chemotherapy to the patient, the management 
of dose and administration of drugs emerged from the ongoing dilemma of cure and danger 
of chemotherapy (Kareva, Waxman & Klement, 2015). It can be given as an injection into the 
bloodstream, a drip into the bloodstream, tablets or capsules, at varied times and doses. 
These are classified as systemic treatment, because the managing of chemotherapy drugs in 
this way allows them to reach cancer cells anywhere in the body with minimal aspired side 
effects (Tobis, Hochhauser & Souhami, 2010) 
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1.7  Medicinal Anti-Cancer Drugs 
Over the preceding fifty years, the evolution of anticancer drugs has changed and diverged 
from conventional cytotoxicity, towards achieving rational designs of selective agents which 
act on specific cellular targets (DeVita and Chu, 2008) (Hambley, 2009). Nevertheless, 
significant challenges remain, and the relationship between structural biology and chemistry 
may offer the most effective ways for discovering and improving upon novel anticancer 
agents (Neidle and Thurston, 2005).  
 
1.7.1 DNA Reactive Agents 
The mechanisms of DNA reactive agents are yet to be completely determined and difficulties 
with their use of growing resistance have made them a complex succession of compounds to 
use efficiently. An example of a recognised family of DNA reactive agents are cisplatin and its 
derivatives including oxaliplatin and carboplatin (Fig 6), which act through the development 
of DNA-drug adducts leading to prevention of DNA replication and the initiation of apoptosis 
(Doak et al., 1998). These platinum derived compounds are found to be effective in treating 
many types of cancers such as ovarian, head, neck and bladder. They have especially been 





There are several checkpoints on a cell cycle that generate the production of regulatory 
protein if the abnormalities such as irregular or damaged DNA are detected during the process 
Figure 6 Chemical structures of Platinum containing compounds, Cisplatin, Carboplatin and Oxaliplatin, 
which are widely used as anti-cancer agents 
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of cellular replication. The development of adducts on the DNA will cause prevention in the 
replication of DNA during mitosis and thus instead trigger the process of apoptosis (Cavalieri 
et al., 2017).   
1.7.2 Platinum based Agents including Cisplatin 
Carrying on from the claim laid down by Ott & Gust (2007), ‘almost all drugs placed in the 
market are organic non-metal substances, Sumntharalingam et al., (2012) report that 
currently the majority of anti-cancer drugs in use or clinical trials are organic in nature, 
currently relying on mechanisms of action which involves the damage of nucleic acids (Glazer, 
2013). Even though the modern use of pharmacologic agents to treat cancer began in the mid 
1940’s, where the efficacy of nitrogen mustard in tumour bearing mice was highlighted by 
Alfred Gilman and Louis Goodman. 
Discovered by Michele Peyrone in 1844, Cisplatin (cis-diamminedichloroplatinum(II)), was 
actually given world-wide recognition nearly a century later in 1960, when Barnett Rosenberg 
discovered the tumor-inhibiting characteristics it exhibited (Ndagi, Mhlongo, & Soliman, 
2017). Aydin et al., (2014) further mention that the discovery of the anticancer activity in 
cisplatin helped trigger the development of novel drugs which contain metals such as 
platinum or ruthenium. 
The location in the cell responsible for the activation of cisplatin is the cytoplasm. This is 
where chloride ions dissociate and are replaced by water molecules. This transformation of 
[cis-Pt(Cl)2(NH3)2] to the mono-aqua [cis-(NH3)Pt(Cl)2(OH)2)]+ and di-aqua [cis-
Pt(Cl)2(OH2)2]2+ leads to an increase by 1000 times in comparison to standard cisplatin 
(Dasari & Tchounwou, 2014). The converted potent electrophile from the hydrolysed 
platinum complex reacts the nucleotides available such as the sulfhydryl groups present on 
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proteins and nitrogen donor atoms existing on nucleic acids that make up DNA. The 
hydrolysed product of cisplatin forms covalent bonds to the N7 reactive centre on purine 
residue and stabilises causing DNA damage, blocking cell division and triggering apoptosis 
(Dasari & Tchounwou, 2014) (Bracht, Grünert & Bednarski, 2006).   
Entering clinical experiments shortly after its ‘discovery’, the drug became highly active and 
popular amongst the world-wide audience in treating symptoms such as testicular, bladder 
and neck tumours in addition to ovarian carcinomas, with Ott & Gust (2007) labelling it the 
best-selling anticancer drug worldwide. Suntharalingam et al., (2012) agree with this 
proposition, by adding that Cisplatin and its derivatives such as oxaliplatin and nedaplatin are 
widely used to treat cancers of all forms, with Platinum drugs being used ca. 50% in all 
chemotherapeutical treatment. This was a breakthrough, since the tumours it attacked were 
mainly solid tumours. Initially it was observed that Cisplatin induced a filamentous growth in 
bacteria without it affecting any RNA or protein synthesis, which led to suggest that DNA was 
the primary target of the drug (Johnson, O’Dwyeer, & Stevenson, 2006). However, the 
presence and development of side effects and drug resistance often leads to treatment failure 
(Bielefeld et al., 2013), with apparent clinical drawbacks including limited applicability, 
acquired resistance and side effects such as neurotoxicity and nephrotoxicity (Bruijnincx & 
Sadler, (2008) Frezza et al., (2011). It has also been reported that it readily reacts with non-
target tissues. In addition to this, cisplatin has limited solubility available in an aqueous 
solution thus restricting its administration intravenously whereby these shortcomings only 
occur due to the lack of tumour selectivity Cispltin exhibits, leading the cause for new and 
novel compounds to be designed, which are therefore able to accumulate in specific target 
cells and help overcome the shortcomings and side effects found in cisplatin (Gabano, Ravera, 
& Osella, 2009) 
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Mono adducts can result due the formation of adducts; intra- as well as interstrand crosslinks. 
Instrastrand crosslinks appear when the platinum adducts form on neighbouring bases on the 
same strand of DNA, while interstrand crosslinks occur when adducts form between two 
separate strands (Dasari & Tchounwou, 2014) (Koster et al., 2013). Intrastrand adducts are 
projected to shape an approximate of 90% of adducts, whereas, interstrand and 
monofunctional adducts are theorised to add to the toxicity of the platinum-based remedies 
(Koster et al., 2010). Adduct formation progresses towards destruction of DNA duplex as the 
intrastrand crosslinks curve the strand in the direction of the major groove leading to the 
exposure of a lesser groove at which site several classes of protein bind, such as repair 
proteins (Alnajjar & Sweasy, 2019).  
There are two cisplatin induced concentration types of death; necrosis and apoptosis. 
Necrosis is distinguished by cytosolic swelling with loss of the plasma membrane integrity and 
is associated with exposure to high concentrations exceeding 800 µM of cisplatin. On the 
other hand, exposure to concentrations as low as 8.0 µM over several consecutive days will 
cause apoptosis and thus, cell reduction, chromatin condensation and DNA fragmentation 
(Kim, He & Lemasters, 2003). The core response of closely monitored therapeutic treatments 
is apoptosis and has two adapted paths in mammals. One is the extrinsic pathway that 
includes the ligand binding to the tumour necrosis factor (TNF-α) which causes the adoption 
of caspase -3, -7, -8 and -9, these ultimately activate the associated death domain proteins to 
death receptors that cause cell death (Gonzalez, Hagerling & Werb, 2018). On the other hand, 
the intrinsic apoptotic pathway includes the adjustment of potential of the mitochondrial 
membrane causing the release of cytochrome c and the adjustment of apoptotic gene 
regulation. This process requires the upregulation of the pro-apoptotic gene Bax with 
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synchronized downregulation of the anti-apoptotic gene Bcl-2, crucial in proliferation 
(Balkwill, 2009) (Gonzalez, Hagerling & Werb, 2018). 
Theoretically, there are two main mechanisms associated with cisplatin uptake. In the 
instance of the platinum complex concertation increasing at a linear rate within the first hour 
of administration with a deficiency of saturation up to the concentration of 1.0 mM, the 
mechanism of passive diffusion is granted (Wang & Lippard, 2005) (Balkwill, 2009).  
Complexes with platinum bases are assumed to utilise the CRT1 protein as a means of 
transport into the cell, replicating the way copper enters the cell. It has been found that when 
the genetics of the CRT1 protein are mutated or deleted there has been an increase in 
resistance to platinum-based therapies, while upregulation of CRT1 intracellular levels lead 
to sensitisation of the cell (Wang & Lippard, 2005).  
A growing issue is associated to the increase in the resistance of platinum-based drugs. There 
are two modes of resistance that are a main cause of concern, one being the deficiency of 
drug delivery to the target site and the other is the genetic and epigenetic alterations that 
affect sensitivity to the agent (Chen et al., 2013). There can be several factors responsible for 
the reduced concentration of the agent reaching the desired target site and therefore causing 
a limitation in the potential therapeutic effects of the administered drug. These can be poor 
bioavailability of the compound, an increase rate of metabolism, and an increase in the rate 
of excretion from the body (Chen et al., 2013). Cancer cells can become resistant through 
alteration of the drugs cellular target, upregulation of genes involved in the repair of drug 
induced damage especially to DNA, enhanced bypass of DNA adducts, increased tolerance to 
DNA damage, and increased levels of detoxification through increased cellular thiol 
production (Chen et al., 2013) (Ohmichi et al., 2005). If resistance is displayed to one 
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therapeutic agent, then cells may begin to present resistance to drugs that may be structurally 
and mechanically unrelated identified as a process called multidrug resistance (Ohmichi et al., 
2005).  
The foundation of the major drawbacks of platinum-based drugs are their side effects due to 
their highly toxic limiting the potential administration concentration. They also have the 
tendency to interact with non-target tissue and are highly neuro- and nephrotoxic (Wang & 
Lippard, 2005) (Chen at al., 2013). The nephrotoxicity is speculated to be due to the intrinsic 
activation of protein kinases, the assembly of reactive oxygen species (ROS), and the stimulus 
of fibrogenesis at the site of action (Ben Saad et al., 2017) (Chen et al., 2013). The application 
of platinum-based chemotherapy has also been associated with tinnitus, hearing loss and 
peripheral neuropathies with the likes of loss of vibrational sense and weakness. These side 
effects are due to the unwanted cisplatin interaction with dorsal root ganglia and peripheral 
nerves leading to cisplatin induced apoptosis (Ohmichi et al., 2005). 
The use of carboplatin has benefits due its properties of being the six-member ring 
conjugation with platinum, as it provides aqueous stability, which increases the half-life of the 
treatment while not impacting the clinical activity and demonstrating fewer side effects, from 
1.5 to 3.6 hours to in excess of 30 hours. However, the administration does not override 
cisplatin resistance (Wang & Lippard, 2005). Additionally, Oxaliplatin form similar adducts on 
the same site on DNA as cisplatin, however, their structural differences cause a difference in 
identity by repair proteins, leading to oxaliplatin being able to overcome cisplatin resistance 
(Ben Saad et al., 2017). 
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1.8 Antimetabolites 
Antimetabolites are a drug class referred to as one of the very first examples of rational design 
of a drug (Liu & Gerson, 2016). In 1946 by Spies it was discovered that with the intake of folic 
acids there was an escalation in the proliferation of lymphoblastic leukaemia cells, and this 
led to its administration to patients experiencing megaloblastic anaemia, leading to 
stimulation of maturation and progression of bone marrow. Folate analogues like 
Aminopterin and Methotrexate (MTX) (Figure 7) were discovered to block folic acid thus, 








Mammalian cells do not have the ability to produce folates de novo, these also do not possess 
the ability to cross the biological membrane through the process of diffusion due to their 
hydrophilic properties, causing the cells to be reliant on locating folates from a series of 1-
carbon reactions (Matherly, Hou & Deng., 2007). In order to enhance the retaining volume, 
intracellular folate folylpolyglutamate synthetase (FPGS) combines glutamate to folate 
reducing its efflux from the cell and an identical process is undergone on MTX. MTX is 
converted to methotrexate polyglutamate (MTXPG) causing improved preservation in cells. 
Figure 7 Chemical structures of Aminopterin and Methotrexate 
(MTX), which block the production of folic acid 
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As the polyglutamate metabolites are weak substrates for MTX efflux proteins, the reaction 
contributes to the efficacy of the MTX therapy (van de Steeg et al., 2009).  
Antimetabolites imitate the behaviour of molecules found in the cell and hinders DNA 
replication with the aid of a DNA antagonist accountable for blocking nucleotide metabolism 
pathways (Cheung-Ong et al., 2013). MTX is a common form of treatment for several cancers 
including leukaemia, non-small cell lung, bladder, neck and choriocarcinoma in which the rate 
of success exceeds 90%. Its mechanism of action arises inhibition of dihydrofolate reductase 
(DHFR) which catalyses the decline of dihydrofolate to tetrahydrofolate, essential in the 
production of DNA (van de Steeg et al., 2009) (Xie et al., 2009). MTX interferes with purine 
and pyrimidine production which are crucial for the replication of DNA. MTX use causes a 
reduction in the amount of tetrahydrofolate avail and ultimately of the necessary nucleotides. 
This decline in nucleotide concentration leads to a decrease in cell population and the 
initiation of programmed apoptosis (van de Steeg et al., 2009). 
Levels of DHFR expression can be an indicator for the level of response of MTX treatment, 
however, this is not always the case due to the establishment of a secondary mechanism. This 
secondary pathway includes stimulation of genetic injury through mechanisms such as; gene 
mutation, direct DNA damage, oxidative damage and chromosomal aberration. Xie and 
colleagues (2009) also explain that MTX demonstrates apoptosis through paths activated in 
response to DNA mismatch repair malfunctions, like the development of double strand breaks 
and the inhibition of homologous recombination that accompanies MTX use.  
MTX and other anti-folate drugs, are sufferers of resistance which can arise from the loss or 
mutation of a cell surface receptor or target. In cases of such instance, anti-folates would be 
incapable of reducing the conversion of dihydrofolate to tetrahydrofolate, thus the 
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production of nucleotides will not be affected causing the potential for uncontrolled DNA 
replication and cellular proliferation (Cheung-Ong et al., 2013). 
1.9 Antimitotics 
Antimitotics including the vinca alkaloids and toxoids are a further class of anticancer 
therapeutics. Vinca alkaloids were first extracted from the Madagascar periwinkle plant and 
are comprised of two multi-ring constructs (Mora et al., 2015) (Douer, 2016).   
Vincristine and vinblastine are two most commonly utilised vinca alkaloids entailing the 
mechanism where the prevention of formation of spindle microtubules during the cell cycle 
leads to ceasing replication progression (Douer, 2016).  
1.10 β-Diketones  
β-Diketones have been a subject of study over a century and have been studied for properties 
in the treatment of osteoporosis, trauma, depression, and diabetes (Ara and Khan, 2014).  It 
is also regarded as an appropriate Wnt activator, a pathway that starts developing of 
malignant and benign breast cancer (Figure 8) (Wallace et al., 2013) (Khan et al., 2018).  




Commercially, β-diketone is used in the manufacture of a wide variety of synthetic polymer 
materials including polyvinyl chloride to acrylonitrile butadiene styrene (ABS)  
Figure 8: Wnt signalling is activated when 
secreted Wnt ligands bind to the seven-
pass transmembrane receptor Fzd (dark 
blue) and the single-pass low-density 
lipoprotein receptor-related protein (LRP) 
(light blue). LRP is phosphorylated, 
leading to the recruitment and 
polymerisation of Dvl proteins (red) at the 
plasma membrane. 
 
The Dvl polymer (active) inactivates the 
destruction complex; consisting of AXIN, 
adenomatous polyposis coli (APC), and 
GSK3β, leading to the stabilisation and 
cytoplasmic accumulation of β-catenin 
(orange) which then translocate to the 
nucleus.  
 
When inside the nucleus, β-catenin forms 
a complex with T-cell factor (TCF) and 
lymphoid enhancer factor (LEF) (purple), 
acting as a transcriptional switch, that 
changes multiple cellular processes 
 
Figure 8 Overview of the canonical Wnt signalling pathway 
(adapted from (Khan et al., 2018) 
Figure 9 Structure of synthetic polymers which includes the common, acrylonitrile butadiene styrene (ABS) 
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1.10.1  Properties of β-diketones 
Given the stability, nontoxic and exceptional characteristics of β-diketones a huge number of 
applications have been studied by synthetic organic chemist. In addition, their responsiveness 
and synthetic strategies to several members of 1,3-diketoes, these were designed and have 
been tested for therapeutic qualities (Wallace et al., 2013). Members and derivatives of 1,3-
diketones appear in numerous plants such as Eucalyptus leaves and liquorice. Additional long 
chain aliphatic 1,3-diketones are found in Sunflower pollen and vanilla beans and have 
powerful natural antioxidants and prominent anti-cancer properties with minimal toxicity 
(Radi et al., 2015).  
In conjunction with the medicinal properties, β-diketones have also been utilised in sunscreen 
products in the United States (Andreassi, 2011). In addition, most β-diketones already known 
have an absorption wavelength in the range of ƛ = 300-400nm (Zawadiak et al., 2011) 
β-Diketones have exposed remarkable qualities given their structural orientation, especially 
due to the presence of the two carbonyl groups separated with a methylene group (CH2) 
(Urbaniak et al., 2011). Due to the presence of the less polar hydrogen atom on the enol-
tautomer it is more favourable in inert solvents from the keto-tautomer which seems more 
dominant in the polar solvents (Simoni et al., 2008). Apart from the solvent as a factor 
influencing the equilibrium position of these compounds, substituents attached to the 
carbonyls also lead to equilibrium shift depending upon the nature of the substituting group 
as explained by Liang and colleagues (2008). The keto-enol property of β-diketones establish 
a resilient chelating property and possesses the ability to develop stable complexes together 
with different metals, comprising of transition metals and metals in the lanthanide series 
(Vigato, Peruzzo, & Tamburini, 2009). 
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1.11 A.D.M.E 
The development, description of new drugs and the safe use of approved drugs needs 
knowledge of the pharmacokinetics of the drug. Pharmacokinetics is the summation of the 
rates and scopes of four general processes or factors called absorption or introduction of the 
drug into the individuals’ biological circulation, distribution or the drug administration 
progressing onto extravascular fluids and tissues, metabolism which causes the enzymatic 
changes in drug molecule structure and elimination or excretion which is primarily in urine or 
feces (ADME) (Gu et al., 2018). A comprehensive understanding of the pharmacokinetics of a 
drug is the foundation for modulating the most appropriate dose, route of administration, 
and intervals between doses to deliver the ideal concentrations of the active drug for an 
effective therapeutic effect (Bell et al., 2002).  
The first is absorption with this being initiated once a drug is administered. This entails the 
process of transporting the drugs from the primary site which is the administration site to the 
systemic circulation (Undevia, Gomes-Abuin & Ratain, 2005).  
The most immediate route of drug administration happens through intravenous 
administration; drugs provided through this method are considered to have 100% 
bioavailability. On the other hand, drugs administered orally are prone to absorption 
obstacles in the gastrointestinal tract (Undevia, Gomes-Abuin & Ratain, 2005). Undevia and 
colleagues in 2005 also explain that the absorption of oral drugs is regulated by various factors 
(Budha et al., 2012): 
I. The surface area of absorption of the drug administered 
II. the time needed to travel through the gastrointestinal tract 
III. Blood flow to the relevant site of absorption 
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IV. Intestinal and gastric pH and successive pH dependent solubility 
V. Intestinal efflux and influx conveyance, for example the ATP binding cassette (ABC) 
gene products such as glycoprotein can inhibit the uptake of oral anticancer drugs) 
VI. The rate of intestinal metabolism, for example oral drugs are subject to intestinal 
metabolism by CYP3A4, a subclass of cytochrome p450 enzymes.   
 
Proceeding from absorption, the administered drug distributes from the intravascular space 
to its target in the extravascular space (Budha et al., 2012). Most of the drugs administered 
proceed to bind to the plasma proteins such as albumin. The amount of drug that proceeds 
its target depends on the amount of drug that is successful in binding to plasma proteins, as 
only the fraction of the drug that is free in the body is pharmacologically active (Neidle, 2005).  
Uptake of the drugs in the liver is mediated by one of two processes passive diffusion or active 
transport. Once the administered drug is in the liver, the anticancer drugs undergo phase I 
and phase II metabolic reactions (Undevia, Gomes-Abuin & Ratain, 2005). Phase I reactions 
cause a loss in the pharmacological activity or cause the activation of inactive prodrugs (Van 
Leeuwen et al., 2013). Whereas, Phase II reactions usually cause inactive derivatives for the 
process of excretion. Even though this step is needed for the activation of pro drugs, like 
capecitabine and tamoxifen.  
Drugs interactions linked with excretion are usually credited to renal impairment, which is 
resultant due to either a parent drug or due to co-administration with nephrotoxic agents 
(Undevia, Gomes-Abuin & Ratain, 2005). Majority of the kinase inhibitors undergo hepatic 
dismissal and faecal excretion with varying renal clearance (Landi et al., 2005). Thus, the main 
routes of drug excretion are through the biliary tract and kidneys (Neidle, 2011).  
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1.5.1 Aims of the project 
The aim of this project was to develop simple structure compounds as potential anti-cancer 
agents. Since all compounds in trials or at market are bulky in size, contain various functional 
groups, exhibit significant responses for toxicity however fail when tested within the 
pharmacological parameters.  Therefore, looking at what natural products were already out 
there without the need of altering the substructure too much, a derivative of Curcumin, a 
natural herb, was researched. Dibenzoymethane was shown to already exert it’s chemical and 
biological activity on a range of different cells and illnesses. Without changing the skeletal 
structure of Dibenzoylmethane to much, a plan was actioned to synthesis analogues of the 
molecule, however these derivatives would only have minimal difference from the parent 
compound, be quite easy to synthesise, not very hard to purify and provide enough activity 
to be tested under pharmacological conditions.  The synthesised compounds were then 
studied to see if further changes could be made and then tested on some biological as well as 
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2 Material and Methods 
 
2.1 Synthesis and purification 
 
2.1.1 General procedures for compound purification and determination 
 
All the compounds described were synthesised within the laboratories at the University of 
Salford. The analysis and structural determination of the compounds were carried out by TLC 
(thin layer chromatography), 1H- and 13C-NMR (nuclear magnetic resonance spectroscopy), 
infrared spectroscopy (IR) and melting point analysis.  
Solvents and Reagents 
Anhydrous solvents for the reactions were obtained as follows; 
Dry THF was obtained by distillation over sodium and benzophenone under argon 
atmosphere as required.  
Dry toluene and acetonitrile were dried over activated 3 Å molecular sieves for a period of 24 
hours. 
Any other solvents and reagents used were purchased from Thermo Fisher Scientific.  
Chromatography 
Flash column chromatography was carried out on silica gel 60 Å pore size and a particle size 
of 40-63 µm purchased from Thermo Fisher Scientific.  The column diameter size was 
determined via the amount of dry compound obtained after evaporation. Solvents were 
chosen according to TLC analysis, and mixed solvent systems utilised were in the v/v 
(volumetric ratio) form. The TLCs were carried out on pre-coated aluminium backed silica 
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plates (0.2mm, 60 F254). Rf values determined were calculated to the nearest 0.01 decimal 
place, and the development of the separated products on the plate were visualised at UV254 
(short).  
1H and 13C-NMR 
All NMR spectra were obtained and recorded through the usage of a Bruker AC-400 
spectrometer using CDCl3 as an internal standard unless stated otherwise (7.26 ppm for 1H 
NMR, 77.0 ppm for 13C NMR). Chemical shifts () are given in parts per million (ppm) relative 
to tetramethylsilane (TMS) in addition to the coupling constants (J), which are stated in Hertz 
(Hz) and reported to one decimal place. The solvent peaks were determined from tables giving 
typical solvent shifts in NMR spectroscopy available in the literature (gottlieb, Kotlyar & 
Nudelman, 1997). 
Infra-red 
All spectra were obtained and recorded on Thermo Scientific Nicolet iS10, and the absorbance 
peaks of the compounds reported as wave numbers (cm-1). 
Melting Point 
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2.1.2 General Procedures for synthetic approach 
 
Procedure A 
Under an atmosphere of argon, Potassium tert-butoxide (1.40 eq, 3.49 g, 3.10 x 10-2 mol) was 
suspended in dry THF (50 mL) and cooled to 0oC whilst undergoing stirring, leading to the 
formation of a cloudy, white solution. Added dropwise over a period of 10 minutes was 
acetophenone/s (3.00 g, 2.21 x 10-2 mol) suspended in dry THF (50 mL), forming a yellow 
suspension.  
The reaction mixture was then left to warm to room temperature whilst stirring for a period 
of 30 minutes before it was cooled to 0oC under ice. Benzoyl Chloride substituent/s (1.20 eq, 
3.08 mL, 2.65 x 10-2 mol) was added dropwise using a glass syringe, which led to the formation 
of a yellow solution. The mixture was then left to stir at room temperature, under argon, for 
a period of up to 3 hours.  
After being cooled down to 0oC, potassium tert-butoxide (1.40 eq, 3.49 g, 3.10 x 10-2 mol) was 
again added with stirring and refluxed for 12-24 hours overnight. The mixture was then cooled 
to 0oC before HCl (3M) was added until the desired pH level (2-3) was reached. Using DCM (3 
x 50 mL), the reaction mixture was extracted with the resulting combined organic layers being 
washed with sodium bicarbonate (2 x 50 mL), water (2 x 50 mL) and brine (2 x 50 mL). Using 
MgSO4, the layers were dried and concentrated in vacuo leading to the formation of a 
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Procedure B 
Sodium hydride (0.2 g, 7.5 mmol) was suspended in dry THF (20mL) and the appropriately 
substituted benzoate (0.7 g, 3 mmol) was added whilst stirring. The mixture was then placed 
to cool at 0 0C. The appropriately substituted acetophenone (0.5 g, 2.8 mmol) dissolved in 
anhydrous dry THF (20 mL) was added dropwise over 5-10 minutes. The reaction mixture was 
left to stir at RT for 30 minutes then refluxed for 16h before being cooled to RT. The obtained 
mixture was filtered through Celite, washed with ethanol (3 x 20 mL) and then acidified with 
HCl (10 %) until pH 2 was achieved. The product was extracted with EtOAc (2 x 30 mL), the 
organic layer then washed with brine, water and dried (MgSO4) and concentrated in vacuo 
before being further purified by flash column chromatography (silica, Hexane/EtOAc  4:6). 
The coloured product was obtained as a solid.  
 
 
Figure 10 Scheme to show general synthetic route for 1,3-Diketone production using the base/acid method via reflux 
 
Procedure C 
Into a thick microwave glass vessel was placed the starting acetophenone (0.25 g, 1.5 mmol) 
and the appropriately substituted benzoyl chloride (1 eq, 0.3 mL. 1.5 mmol) with a stirrer 
present. The vessel was allowed to irradiate under the microwave reactor under specific 
conditions (ie, 40 0C, 150MW, 30 minutes). The reaction mixture was allowed to cool before 
being poured onto crushed ice. HCl (10%) was added until a yellow precipitate had formed, 
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and the mixture was filtered. The contained product was extracted with DCM (2 x 25 mL), 
washed with brine, water and dried (MgSO4). Further purification was achieved by flash 
column chromatography (Pet Ether/EtOAc 8:2) to give a solid coloured product.  
Procedure D 
To a solution of chloroimidazolinium hexafluorophosphate (2.35 g, 7.8 mmol) dissolved in 
MeCN (8 mL), sodium azide (717 mg, 11 mmol) was added at 0 °C with the mixture then left 
to stir for 30 minutes. The mixture was filtered through a Celite pad, with the resulting filtrate 
concentrated in vacuo. The obtained residue was then dissolved in MeCN (ca. 2 mL) and the 
solution poured into Diethyl Ether (8mL) to form a precipitate, which was collected via suction 
filtration.  
The resulting white solid (0.6 mmol) was dissolved in MeCN (0.5mL) and cooled to 0 °C. A 
solution of the required 1,3-dicarbonyl compound (0.5 mmol) and Triethylamine (1.0 mmol) 
in THF (2.0 mL) was added and the reaction stirred for a further 30 minutes. The reaction was 
quenched with H2O (5 mL), and the organic materials extracted with Dichloromethane (3 × 
10 mL). The combined extracts were washed with brine (15 mL), and then dried over 
anhydrous Na2SO4. The solvent was removed in vacuo to afford the almost pure diazo 




Figure 11 Scheme to show general synthetic route for 2-Azido-Diketone production 
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Procedure E 
To a solution of ammonium isothiocyanite (0.250g, 5 mmol) in 10 mL acetonitrile, 4-methoxy 
benzoyl chloride (0.64 g, 3.5 mmol) was added dropwise. The reaction mixture was stirred for 
5 minutes until a white precipitate formed. A solution of appropriately substituted analine 
(0.35g, 3 mmol) in acetonitrile (5 mL) was added gradually. The reaction mixture was stirred 
at room temperature for 4 hours and the solvent was evaporated in vacuo. The crude product 
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The above titled compound was prepared from 2-hydroxyacetophenone (3 g, 0.22 mmol) and 
benzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following flash column 
chromatography (SiO2, Hexane:EtOAc 9:2) and recrystallization from methanol, compound 1 
was isolated as a yellow solid (1.56 g , 67%) 
MP: 119 - 121 
1H δ ppm: 3.95 (2H, s), 6.99 (1H, dd, J 1.3, 8.3Hz), 7.36-7.58 (5H, 7.41 (t, J 1.3 7.9Hz), 7.48 (t, J 
1.4 7.3Hz), 7.54 (dd, J 1.4 7.9Hz), 7.53 (dd, 7.2, 1.3, 0.5 Hz)), 7.66 (1H, m), 7.97 (2H,dd J 1.0, 
8.5 Hz). 
13C δ ppm: δ 114.4 (C1), δ 162.4 (C2), δ 118.6 (C3), δ 131.9 (C4), δ 123.4 (C5), δ 129.8 (C6), δ 
199.2 (C7), δ 59.7 (C8), δ 195.1 (C9), δ 134.9 (C10), δ 128.6(C11), δ 128.5(C12), δ 128.5(C13), 
δ 128.5(C14), δ 128.6(C15) 
IR cm-1: 1885, 3100 (O-H), 1720 (C=O) 
 







The above titled compound was prepared from 2,4-dihydroxyacetophenone (2.9 g, 0.18 
mmol) and benzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following flash column 
chromatography (SiO2, Hexane:EtOAc 9:2) and recrystallization from methanol, compound 2 
was isolated as a yellow solid (1.26 g , 56%) 
MP: 164 - 168 
1H δ ppm: δ 3.98 (2H, s), 6.56 (1H, dd, J 1.8), 6.70 (1H, dd, J 1.8, 7.6Hz), 7.53 (2H, dd, J 1.3, 
8.5Hz), 7.66 (1H, t, J 1.5,7.2Hz), 7.93-8.04 (3H, 8.01 (dd, 7.6 Hz), 7.97 (m, J 1.9, 8.5Hz) 
13C δ ppm: δ 102.79 (C1), δ 158.05 (C2), δ 98.73(C3), δ 125.56(C4), δ 159.74(C5), δ 
101.3(C6), δ 197.66(C7), δ 63.22(C8), δ 189.22(C9), δ 127.58(C10), δ 126.87(C11), δ 
125.84(C12), δ 123.66(C13), δ 121.42(C14), δ 121.18(C15) 
IR cm-1: 3049 (O-H), 1746 (C=O) 
 
 







The above titled compound was prepared from 2'-Hydroxy-5'-chloroacetophenone (3.15 g, 
0.29 mmol) and benzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following flash 
column chromatography (SiO2, Hexane:EtOAc 9:2) and recrystallization from methanol, 
compound 3 was isolated as a yellow solid (1.35 g , 62%) 
MP: 135-138 
1H δ ppm: δ 4.00 (2H, s), 6.92 (1H, dd, 8.3Hz), 7.40 (1H, dd, J 1.7, 8.3Hz), 7.53 (2H, dd, J 1.3, 
8.5Hz), 7.66 (1H, t, J 1.5, 7.2Hz), 7.97 (2H, dd, J 1.9, 8.5Hz), 8.06 (1H, d, J 1.7). 
13C δ ppm: δ 119.5 (C1), δ 160.7 (C2), δ 120.0 (C3), δ 130.5 (C4), δ 129.3 (C5), δ 127.6 (C6), δ 
199.2 (C7), δ 59.7 (C8), δ 195.1 (C9), δ 134.9 (C10), δ 128.6(C11), δ 128.5(C12), δ 128.9(C13), 
δ 128.5(C14), δ 128.6(C15) 











The above titled compound was prepared from 4-bromoacetophenone (1.8 g, 0.36 mmol) 
and benzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following flash column 
chromatography (SiO2, Pe:EtOAc 8:2) and recrystallization from methanol, compound 4 was 
isolated as a white solid (0.98 g , 52%) 
MP: 125 - 129 
1H δ ppm: δ 5.98 (1H, s), 7.56 (4H, dd, J 1.4, 8.4Hz), 7.66 (2H, t, J 1.5, 7.4Hz), 7.97 (4H, 
m, J 1.9, 8.4Hz) 
13C δ ppm: δ 135 (C1), δ 126.8 (C2), δ 128.8 (C3), δ 129.5 (C4), δ 128.8 (C5), δ 126.8(C6), δ 
187 (C7), δ 57.3 (C8), δ 187 (C9), δ 135 (C10), δ 126.8(C11), δ 128.8(C12), δ 129.5(C13), δ 
128.8(C14), δ 128.6(C15) 












The above titled compound was prepared from 2-hydroxyacetophenone (2.2 g, 0.29 mmol) 
and 4-methoxybenzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following flash 
column chromatography (SiO2, Pe:EtOAc 10:1) and recrystallization from methanol, 
compound 5 was isolated as a white solid (0.88 g , 52%) 
MP: 121 - 128 
1H δ ppm: δ 3.81 (3H, s), 3.95 (2H, s), 6.57 (1H, d, J 1.3, 6.64 (1H, d, J 1.3, 7.6Hz), 7.53 (2H, 
t, J 1.3 8.5Hz), 7.66 (1H, t, J 1.5,7.1Hz), 7.93-8.03 (3H, 8.00 (dd, 7.6Hz,), 7.97 (dd, J 1.9,8.5Hz) 
13C δ ppm:  114.4 (C1), δ 128.5 (C2), δ 111.3 (C3), δ 161.9 (C4), δ 101.3(C5), δ  164.7(C6), δ 
199.7 (C7), δ 59.7 (C8), δ 195.1 (C9), δ 134.9 (C10), δ 128.6(C11), δ 128.5(C12), δ 128.9(C13), 
δ 128.5(C14), δ 128.6(C15) δ (C16) 












The above titled compound was prepared from 4-methoxyacetophenone (1.16 g, 0.18 
mmol) and 4-methoxybenzoyl chloride (3.1mL, 0.26mmol) as per procedure A. Following 
flash column chromatography (SiO2, Hexane:EtOAc 10:1) and recrystallization from 
methanol, compound 6 was isolated as a white solid (0.58 g , 46%) 
MP: 129 - 134 
1H δ ppm: δ 3.80 (6H, s), 3.94 (2H, s), 7.05 (4H, dd, J 1.2, 8.3Hz), 7.99 (4H, dd, J 1.8,8.3Hz). 
13C δ ppm:  134.9 (C1), δ 130.3 (C2), δ 114 (C3), δ 55.5 (C4), δ 114 (C5), δ  130.3(C6), δ 195.1 
(C7), δ 59.7 (C8), δ 195.1 (C9), δ 134.9 (C10), δ 130.3(C11), δ 114(C12), δ 114(C13), δ 
114(C14), δ 130.5(C15) δ 55.5(C16) δ 55.5(C17) 













The above titled compound was prepared from methyl-3,4,5-trimethoxybenzoate (0.85 g, 
2.3 mmol) and 3-flouro-4-methoxyacetophenone (0.5 g, 2.6mmol) as per procedure B. 
Following flash column chromatography (SiO2, Hexane:EtOAc 4:6) and recrystallization from 
methanol, compound 7 was isolated as a white solid (0.32 g , 68%) 
MP: 123-125 
1H δ ppm: δ 3.77 (6H, s), 3.84 (2H, s), 3.87-3.88 (6H, 3.88 (s), 3.88 (s)), 6.87 (1H, 
dd, J 2.3,7.6Hz), 7.23 (1H, dd, J 2.3), 7.30 (2H, d, J 1.8), 7.96 (1H, dd, J 7.6). 
13C δ ppm:  134.9 (C1), δ 125.7 (C2), δ 114.6 (C3), δ 163.9 (C4), δ 99.8 (C5), δ  158.7(C6), δ 
195.1 (C7), δ 58.5 (C8), δ 199.2 (C9), δ 138.6 (C10), δ 108.2(C11), δ 152.1(C12), δ 139.8(C13), 
δ 152.1(C14), δ 107.5(C15) δ 57.6(C16) δ 60.3(C17) δ 60.3(C18), δ 57.6(C19) 












The above titled compound was prepared from methyl-3,4,5-trimethoxybenzoate (0.85 g, 
2.3 mmol) and 2-flouro-5-methoxyacetophenone (0.65 g, 3.1mmol) as per procedure B. 
Following flash column chromatography (SiO2, Hexane:EtOAc 4:6) and recrystallization from 
methanol, compound 8 was isolated as a white solid (0.37 g , 62%) 
MP: 123-125 
1H δ ppm: δ 3.77 (6H, s), 3.88 (3H, s), 3.92 (3H, s), 3.95 (2H, s), 7.04 (1H, dd, 8.4Hz), 7.30 (2H, 
d, J 1.8), 7.71 (1H, dd, J 1.9, 8.4Hz), 7.78 (1H, dd, J 1.9) 
13C δ ppm:  134.9 (C1), δ 129.5 (C2), δ 112 (C3), δ 152.8 (C4), δ 151.2 (C5), δ  115(C6), δ 
195.3 (C7), δ 59.9 (C8), δ 194.5 (C9), δ 138.4 (C10), δ 108.5(C11), δ 153.8(C12), δ 138.6(C13), 
δ 152.8(C14), δ 108.4(C15) δ 56.6(C16) δ 61.3(C17) δ 57.4(C18), δ 57.4(C19) 












The above titled compound was prepared from methyl-3,4,5-trimethoxybenzoate (0.69 g, 
2.9 mmol) and 3,4,5-trimethoxyacetophenone (0.5 g, 2.38mmol) as per procedure B. 
Following flash column chromatography (SiO2, Hexane:EtOAc 4:6) and recrystallization from 
methanol, compound 9 was isolated as a yellow solid (0.25 g , 32%) 
MP: 87 - 89 
1H δ ppm: δ 3.77 (12H, s), 3.88 (6H, s), 3.95 (2H, s), 7.30 (4H, d, J 1.8 Hz). 
13C δ ppm:  137.8 (C1), δ 109.5 (C2), δ 152.9 (C3), δ 139.8 (C4), δ 152.9 (C5), δ  109.5(C6), δ 
195.1 (C7), δ 57.9 (C8), δ 195.1 (C9), δ 137.8 (C10), δ 109.5(C11), δ 152.9(C12), δ 139.8(C13), 
δ 152.9(C14), δ 109.5(C15) δ 60.9(C16) δ 60.9(C17) δ 56.2(C18), δ 56.2(C19), δ 56.2(C20) δ 
56.2(C21)  











The above titled compound was prepared from methyl-3,4,5-trimethoxybenzoate (0.99 g, 
2.4 mmol) and acetophenone (0.9 g, 2.38mmol) as per procedure A. Following flash column 
chromatography (SiO2, Hexane:EtOAc 4:6) and recrystallization from methanol, compound 
10 was isolated as a yellow solid (0.45 g , 42%) 
MP: 87 - 89 
1H δ ppm: δ 3.77 (6H, s), 3.88 (3H, s), 3.90 (2H, s), 7.23 (2H, d, J 1.8 Hz), 7.53 (2H, t, J 1.3, 
8.5Hz), 7.66 (1H, t J 1.5,7.2Hz), 7.97 (2H, dd, J 1.9, 8.5Hz). 
13C δ ppm:  138.6 (C1), δ 110.4 (C2), δ 151.9 (C3), δ 139.2 (C4), δ 151.9 (C5), δ  110.5(C6), δ 
196.1 (C7), δ 59.9 (C8), δ 197.2 (C9), δ 134.8 (C10), δ 128.5(C11), δ 126.4(C12), δ 128.9(C13), 
δ 126.4(C14), δ 128.4(C15) δ 62.3(C16) δ 58.3(C17) δ 58.3(C18)  












The above titled compound was prepared from acetophenone (2.6 g, 3.4 mmol) and Benzoyl 
chloride (3.5 mL, 3.38mmol) as per procedure A. Following flash column chromatography 
(SiO2, Hexane:EtOAc 4:6) and recrystallization from methanol, DBM was isolated as a white 
solid (1.68 g , 73%) 
MP: 115 - 117 
1H δ ppm: δ 3.75 (2H, s), 7.53 (4H, dd, J 1.3, 8.5Hz), 7.71 (2H, t, J 1.5, 7.2Hz), 7.97 (4H, 
dd, J 1.5, 8.5,Hz). 
13C δ ppm:  136.7 (C1), δ 128.8 (C2), δ 128.6 (C3), δ 133.1 (C4), δ 128.6 (C5), δ 128.8 (C6), δ 
190.4 (C7), δ 93.3 (C8), δ 190.1 (C9), δ 1346.7 (C10), δ 128.8(C11), δ 128.6(C12), δ 
133.1(C13), δ 128.6(C14), δ 128.8(C15) 
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Using procedure D, the resulting white solid (1.24g, 0.6 mmol) was dissolved in MeCN 
(0.5mL) and cooled to 0 °C. A solution of 1,3-diphenylpropane-1,3-dione (2.4 g) and 
Triethylamine (1.0 mmol) in THF (2.0 mL) was added and the reaction stirred for a further 30 
minutes. The reaction was quenched with H2O (5 mL), and the organic materials extracted 
with Dichloromethane (3 × 10 mL). The combined extracts were washed with brine (15 mL), 
and then dried over anhydrous Na2SO4. The solvent was removed in vacuo to afford the 
almost pure diazo compound (1.8 g, 87%). The crude material was purified by flash column 
chromatography (Ethyl Acetate:Hexane 10:2) 
MP: 149 - 153 
1H δ ppm: δ 7.45 (4H, dd, J 1.4, 8.4Hz), 7.62 (2H, t, J 1.5, 7.4Hz), 7.98 (4H, m, J 1.9, 8.45 Hz). 
13C δ ppm:  134.7 (C1), δ 130.3 (C2), δ 128.6 (C3), δ 129.5 (C4), δ 128.6 (C5), δ 130.8 (C6), δ 
185.4 (C7), δ 153.3 (C8), δ 185.1 (C9), δ 134.7 (C10), δ 130.8(C11), δ 128.6(C12), δ 
129.5(C13), δ 128.6(C14), δ 130.8(C15) 
IR cm-1: 1420 (C=N), 1762 (C=O) 







Using procedure D, the resulting white solid (1.24g, 0.6 mmol) was dissolved in MeCN 
(0.5mL) and cooled to 0 °C. A solution of 1-(2-hydroxyphenyl)-3-phenylpropane-1,3-dione 
(2.12 g) and Triethylamine (1.0 mmol) in THF (2.0 mL) was added and the reaction stirred for 
a further 30 minutes. The reaction was quenched with H2O (5 mL), and the organic 
materials extracted with Dichloromethane (3 × 10 mL). The combined extracts were washed 
with brine (15 mL), and then dried over anhydrous Na2SO4. The solvent was removed in 
vacuo to afford the almost pure diazo compound (1.48 g, 89%). The crude material was 
purified by flash column chromatography (Ethyl Acetate:Hexane 10:2) 
MP: 149 - 153 
1H δ ppm: δ 6.90 (1H, t, J 1.3,8.3Hz), 7.33-7.53 (4H, 7.45 (m, J = 1.4, 8.4Hz), 7.50 (dd, J =1.4, 
8.1Hz), 7.38 (dd, J = 1.3, 8.1Hz)), 7.49 (1H, t, J =1.4, 8.3Hz), 7.62 (1H, t, J 1.5, 7.4Hz), 7.98 (2H, 
dd, J 1.5, 8.4Hz). 
13C δ ppm:  119.4 (C1), δ 160.4 (C2), δ 116.6 (C3), δ 133.9 (C4), δ 123.4 (C5), δ 129.8 (C6), δ 
183.2 (C7), δ 159.7 (C8), δ 183.1 (C9), δ 132.9 (C10), δ 128.6(C11), δ 128.5(C12), δ 
129.5(C13), δ 128.5(C14), δ 128.6(C15) 
IR cm-1: 1635, 1430 (C=N), 1760 (C=O), 3430 (O-H) 







Using procedure D, the resulting white solid (1.24g, 0.6 mmol) was dissolved in MeCN 
(0.5mL) and cooled to 0 °C. A solution of 1-(5-chloro-2-hydroxyphenyl)-3-phenylpropane-
1,3-dione (1.86 g) and Triethylamine (1.0 mmol) in THF (2.0 mL) was added and the reaction 
stirred for a further 30 minutes. The reaction was quenched with H2O (5 mL), and the 
organic materials extracted with Dichloromethane (3 × 10 mL). The combined extracts were 
washed with brine (15 mL), and then dried over anhydrous Na2SO4. The solvent was 
removed in vacuo to afford the almost pure diazo compound (1.12 g, 85%). The crude 
material was purified by flash column chromatography (Ethyl Acetate:Hexane 10:2) 
MP: 163 - 172 
1H δ ppm: δ 6.95 (1H, dd, 8.3Hz), 7.36-7.50 (3H, 7.39 (dd, J 1.7, 8.3Hz), 7.45 (dd, J 1.4, 
8.4Hz), 7.62 (1H, t, J 1.5, 7.4Hz), 7.98 (2H, dd, J 1.5,8.4Hz), 8.18 (1H, dd, J 1.7). 
13C δ ppm:  121.5 (C1), δ 162.7 (C2), δ 120.0 (C3), δ 133.5 (C4), δ 128.3 (C5), δ 127.6 (C6), δ 
186.2 (C7), δ 59.7 (C8), δ 183.1 (C9), δ 136.9 (C10), δ 130.6(C11), δ 129.5(C12), δ 127.9(C13), 
δ 128.5(C14), δ 130.6(C15) 
IR cm-1: 1724, 1346 (C=N), 1800 (C=O), 3243 (O-H), 755 (C-Cl) 
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As per Procedure E to a solution of ammonium isothiocyanite (0.250g, 5 mmol) in 10 mL 
acetonitrile, 4-methoxy benzoyl chloride (0.64 g, 3.5 mmol) was added drop-wise. The 
reaction mixture was stirred for 5 minutes until a white precipitate formed. A solution of 4-
triflouromethyl aniline (0.35g, 3 mmol) in acetonitrile (5 mL) was added gradually. The 
reaction mixture was stirred at room temperature for 4 hours and the solvent was 
evaporated in vacuo. The crude product was purified by column chromatography (hexane: 
ethylacetate, 8:3) to give a white product (0.28 g, 48%) 
MP: 120-124 
1H δ ppm: δ 3.85 (3H, s), 7.04 (2H, dd, J 1.2, 8.3Hz), 7.11 (2H, dd, J 1.4,8.2Hz), 7.57 (2H, 
dd, J 1.7, 8.2 Hz), 8.02 (2H, t, J 1.8, 8.3Hz). 
13C δ ppm:  133.1 (C1), δ 131.2 (C2), δ 113.7 (C3), δ 160.4 (C4), δ 113.6 (C5), δ  131.2(C6), δ 
167.3 (C7), δ 178.5 (C8), δ 137.7 (C9), δ 116.2 (C10), δ 127.9(C11), δ 129.1(C12), δ 
127.9(C13), δ 116.8(C14), δ 124.3(C15) δ 54.2(C16) 
IR cm-1: 1200 (C-N), 1239 (C-F), 1700 (C=O), 3340 (N-H), 1225 (-OCH), 650 (C-S) 







As per Procedure E to a solution of ammonium isothiocyanite (0.21g, 2.73 mmol) in 10 mL 
acetonitrile, 4-methoxy benzoyl chloride (0.46 g, 3.5 mmol) was added drop-wise. The 
reaction mixture was stirred for 5 minutes until a white precipitate formed. A solution of 
3,4,5-trimethoxy aniline (0.43g, 2.4 mmol) in acetonitrile (5 mL) was added gradually. The 
reaction mixture was stirred at room temperature for 4 hours and the solvent was 
evaporated in vacuo. The crude product was purified by column chromatography (hexane: 
ethylacetate, 8:3) to give a white product (0.32 g, 44%) 
MP: 164- 172 
1H δ ppm: δ 3.69 (3H, s), 3.81 (6H, s), 3.85 (3H, s), 6.31 (2H, d, J 1.5), 7.04 (2H, 
m, J 1.2,8.3Hz), 8.02 (2H, dd, J 1.8, 8.3Hz). 
13C δ ppm:  133.9 (C1), δ 132.6 (C2), δ 109.2 (C3), δ 161.2 (C4), δ 109.2 (C5), δ  132.6(C6), δ 
165.3 (C7), δ 176.3 (C8), δ 140.5 (C9), δ 104.2 (C10), δ 154.5(C11), δ 134.2(C12), δ 
154.3(C13), δ 104.2(C14), δ 62.9(C15) δ 56.2(C16) δ 56.2(C17) δ 55.8(C18) 
IR cm-1: 1146 (C-N), 16130 (C=O), 3140 (N-H), 1163 (-OCH), 612 (C-S) 
 
 







As per Procedure E to a solution of ammonium isothiocyanite (0.30g, 3.6 mmol) in 10 mL 
acetonitrile, 4-methoxy benzoyl chloride (0.46 g, 3.5 mmol) was added drop-wise. The 
reaction mixture was stirred for 5 minutes until a white precipitate formed. A solution of 
aniline (0.56g, 2.9 mmol) in acetonitrile (5 mL) was added gradually. The reaction mixture 
was stirred at room temperature for 4 hours and the solvent was evaporated in vacuo. The 
crude product was purified by column chromatography (hexane: ethylacetate, 8:3) to give a 
white product (0.42 g, 47%) 
MP: 164- 172 
1H δ ppm: δ 3.76 (3H, s), 3.85 (3H, s), 6.69 (2H, dd, J 2.7,8.8Hz), 7.04 (2H, dd, J 1.2, 8.3Hz), 
7.20 (2H, t, J 2.2, 8.8Hz), 8.02 (2H, m, J 1.8, 8.3Hz). 
13C δ ppm:  130.9 (C1), δ 134.2 (C2), δ 113 (C3), δ 164.2 (C4), δ 113 (C5), δ  131.5(C6), δ 
167.3 (C7), δ 178.6 (C8), δ 130.2 (C9), δ 121.5 (C10), δ 114.3(C11), δ 156.3(C12), δ 
114.4(C13), δ 120.4(C14), δ 61.2(C15) δ 56.8(C16) 
IR cm-1: 1237 (C-N), 1785 (C=O), 3234 (N-H), 1236 (-OCH), 685 (C-S) 
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2.2 Experimental – Biological Assays 
 
2.2.1 Subculture and cell maintaince 
 
Culture Media 
100mL of fresh culture media contained the following; RPMI-1640 (88mL), Foetal Bovine 
Serum (10mL), L-Glutamine (1mL) and Penicillin-Streptomycin (1mL) 
Thawing of adherent cells 
For this procedure, two T75 flasks were prepared per vial (ca. 1.5mL) of frozen cells. The 
cryovial which contained the frozen cell stocks were taken from liquid nitrogen or a freezer 
storage (-80°C) and allowed to thaw in a 37 °C water bath (ca 3 min), after being thoroughly 
cleaned using ethanol in sterile conditions. 0.6 mL of the cell suspension was then transferred 
and mixed into fresh culture media (ca 10 mL) and the following centrifuged at 1500rpm for 
5 minutes to remove any excess DMSO. The pellet, obtained after the discarding of the media 
suspension, was mixed in fresh culture media (12 mL) and pipetted into the sterile T75 flasks. 
After an incubation period of 24 h, when microscopy showed that the cells had attached to 
the surface of the flask, the medium was removed and replaced with 12 mL of fresh culture 
medium to prepare the cells for sub-culturing. 
General subculture of adherent cells 
Adherent cells were sub-cultured from one T75 flask into 3 x T25 flasks. Firstly, the old 
medium from the T75 flask was discarded, and the cells on the surface of the flask were 
washed with sterile phosphate buffer (1x PBS v/w, 3 x 5mL for T25 / 3 x 8mL for T75). To 
detach the cells from the surface, trypsin-EDTA (2mL for T25/5mL for T75) was added before 
the flask/s were incubated for 3-5 min at 37 °C. This step was confirmed using a light 
77 | P a g e  
 
microscope. The cells, in suspension, were then re-suspended in fresh culture media (7 mL) 
to inactivate the trypsin-EDTA before being centrifuged at 1500rpm for 5 minutes. The 
obtained pellet, after discarding the suspension, was mixed in fresh culture media (8mL) 
before ca. 2mL was pipetted into each T25 flask. The T25 flask was topped up using 6mL of 
fresh culture media, with the cells left to adhere and proliferate in a humidified incubator 
(37 °C, 5% CO2). The subculture of cells was routinely carried out every two to three days 
depending on the cell confluence and usage of the cells.  
Freezing of adherent cell stock 
Three confluent T25 tissue culture flasks were prepared and used as cell stocks to be stored 
in liquid nitrogen. Cells were detached as per the subculture protocol and fresh culture media 
(5mL) was added to one of the T25 flasks. The cells were suspended, and the suspension 
mixture transferred to the second T25 flask.  Again, the mixed cell suspension was transferred 
to the final T25 flask, whereby a concentrated cell suspension was obtained. This was then 
centrifuged at 1500rpm for 7 minutes, and the supernatant discarded. The obtained pellet 
was then resuspended in foetal bovine serum (5mL containing 10% DMSO). Aliquots (1.5mL) 
were prepared in cryovials and transferred into an isopropanol freezing container to be frozen 
at -80°C overnight, before being stored in liquid nitrogen at -196°C to a long-term storage.  
2.2.2 Drug Dilution 
Drug candidates, including Cisplatin and Chlorpromazine, were prepared as concentration 
stocks in DMSO at 3.33 mM 
The following concentrations were prepared from the stock and stored at 4 °C; 100uM, 50uM, 
25uM, 12.5uM, 6.25uM, 3.125uM 
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The diluted concentrations were prepared using complete cell culture media into 1.5mL 
aliquots. 
2.2.3 MTT Assay 
MTT assays were performed for all synthesised compounds on all the cell lines which were 
grown, as described previously. As per the subculture protocol, cells were obtained and 
detached, ready to use. The pellet obtained was suspended in complete cell culture media 
(10mL) in order to obtain a homogeneous cell suspension. A volume of 10 µL was taken from 
the suspension mixture and the number of cells present within were counted on a C-Chip 
disposable haemocytometer slide (Neubauer improved grid). As a 96-well plate was being 
used for the assay, each well contained ca. 4000 cells per well, and was pipetted with 100 µL 
of the diluted cell suspension. The cell suspension was diluted to the required concentration 
dependant on the calculation of the number of cells present, coupled with the addition of 
fresh complete cell media. The diluted cell suspension (11mL), in a sterile reservoir, was 
pipetted using a multichannel pipette (100 µL per well) in to a flat-bottom treated 96-well 
plate. The plates were then stored to allow cell adherence in an incubator (37 °C, 5% CO2) for 
24 h. The drug candidates in the diluted concentrations (100 µL) were then added onto the 
cells in each well of the 96-well plate in triplicate on duplicate plates, whereby the drug 
concentration increased going down the plate. The plates were then incubated for specific 
time periods; 24 h, 48 h, 72 h and 96 h. 
Following the incubation period, MTT solution (50 µL; 3 mg/mL in PBS) was added to each 
well and the plate incubated for a further 3 h. The plate wells were then carefully aspirated 
to remove all the liquid, care being taken not to disrupt the cells or purple formazan crystals 
which had formed. DMSO (100 µL per well) was added enabling the crystals to dissolve, 
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whereby different shades of purple were observed, and the optical densities of the wells read 
on a spectrophotometer plate reader (Multiskan Ascent, Thermo Labsystems) at 540nm with 
690nm set as a background reading. Data analysis on the collected readings allowed for mean 
values and the standard deviation to be calculated, thus enabling graphical plots to highlight 
dose response vs change in optical density to be plotted. The control sample, fresh cell culture 
media only, was normalised to 100 % cell growth. The obtained graphical plots allowed for 
the determination of the IC50 values (where 50 % of the cell growth was inhibited) for each 
drug candidate tested.  
 
2.3 Experimental – Pharmacological Assays 
 
2.3.1 Plasma Stability Assay 
For each compound, from a stock solution (1mM) in DMSO (5 mL), 1µL of stock (1mM) was 
dissolved in 990 µL of MeOH. This provided a final working standard of 1µM. Stock solutions 
were then stored at -20 0C. Human plasma (Sigma Aldrich), stored at -20 0C, was allowed to 
thaw at RT, before being centrifuged (12000rmp, 7 min) to remove any debris. Phosphate 
buffer (pH 7.4, 100 mL) was formulated by adding Na2HPO4.7H2O (2.02 g) to NaH2PO4H2O 
(0.33 g) in a container with distilled water (80 mL). The pH of the solution was then adjusted 
using HCl or NaOH before being topped up with distilled water to a final volume of 100 mL. 
Eppendorf tubes (7 x 3 sets, 2mL) were labelled accordingly with the time intervals and placed 
in the fridge (4 0C) until use. The concentrations of plasma (50% and 100%) were made up 
using the phosphate buffer (pH 7.4). The conditions were as follows; Control (50 µL of 
phosphate buffer), 50% plasma (25 µL of phosphate buffer and 25 µL of plasma) and 100% 
plasma (50 µL of plasma). Time intervals (mins) were set as 0, 5, 15, 30, 45, 60 and 120 
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A total of 84 tubes for one compound were made and Rifampicin was used as a control drug. 
Each compound (1 µL) was added to each tube and mixed gently but firmly. The tubes were 
then placed in an incubation water bath at 37 0C for the time intervals mentioned above. Ice 
cold methanol (250 µL) was added to each tube at the appropriate time interval in order to 
cease the activity of the reaction. The collected tubes were placed in a micro centrifuge 
(14000rpm, 20 min) and the supernatant removed, using a pipette, into new tubes, which 
were labelled appropriately. The samples were stored at -80 0C until further use and analysed 
via HPLC to detect the change in concentration. This was then plotted as Percentage test 
compound remaining vs time in order to observed compound degradation. 
The study was conducted in triplicate. 
 
2.3.2 S9 Fraction Stability Assay 
S9 fraction was obtained from the storage condition (-20 0C) and allowed to thaw carefully at 
RT. 1 mL of the stock S9 Fraction (20mg/mL) was removed carefully and place into a new tube, 
with the stock returned to storage immediately. Warm Phosphate buffer (37 0C, pH 7.4, 18 
mL) was added to the tube containing the S9 fraction and placed into an incubator (37 0C), 
with the standard working volume now at 1mg/mL. In a separate tube, NADPH (50mM) was 
prepared in phosphate buffer (2 mL, 7.4 pH). 
Once again, Rifampicin was used as a control drug, and each compound had a total of 36 tubes 
prepared. Tubes were prepared as control (500 µL of phosphate buffer at 7.4 pH) and Treated 
(500 µL of freshly prepared S9 Fraction). The metabolic activity was studied at time intervals 
(min); 0, 5, 15, 30 and 45 at 37 0C.  
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Each compound (1 µL) was added to each tube and mixed gently but firmly. 10 µL of the 
NADPH stock was added immediately and the tubes were then placed in an incubation water 
bath at 37 0C for the time intervals mentioned above. Ice cold methanol (750 µL) was added 
to each tube at the appropriate time interval in order to cease the activity of the reaction. In 
high-throughput stability assay for enzymatic reactions within biological matrices such as 
microsomes or plasma, organic solvents such as MeoH or ACN are readily used to stop the 
reaction by allowing the denaturation of the proteins (Di Li et al, 2003,2004).  The collected 
tubes were placed in a micro centrifuge (14000rpm, 20 min) and the supernatant removed, 
using a pipette, into new tubes, which were labelled appropriately. The samples were stored 
at -80 0C until further use and analysed via HPLC to detect the change in concentration. A plot 
of Percentage compound remaining vs time was then analysed in order to calculate 
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3 Results & Discussion 
 
3.1  Synthesis of compounds and analogues  
 
All the compounds which were synthesised as mentioned in 2.1.2  























































Dibenzoylmethane (DBM), (C6H5C(O))2CH2, is an organic compound and subsists as a 1.3-
diketone, but the compound occurs primarily as the enol tautomer (Thomas, Florence and 
Wilson, 2009). The interconversion concerning the diketones and the two corresponding 
enols is so swift that the difference is generally overlooked. DBM has the presence of a white 
solid, and the derivatives such as avobenzone have established applications such as sunscreen 
products (Zawadiak and Mrzyczek, 2010).  
DBM is a natural phytochemical established as a minor component in the root extract of 
liquorice. DBM has shown to avert the formation of DNA-adducts encouraged by carcinogens 
in both vivo and vitro studies. DBM prompt apoptosis in human prostate and colon cancer 
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3.1.2 β-Diketones and Synthesis 
Over the past decade there have been several publications outlining the various techniques 
for the synthesis of β-diketones and their derivatives. There are some publications that 
mention a facile route to produce β-diketones as a precursor to targeted compounds like 
chalcones as well as some medicinal heterocyclic compounds (Sambaiah et al., 2017) (Kel’in, 
2003). 
However, the most widespread and well-recognised procedure for the synthesis of β-
diketones is one that involves Claisen acylation and carbethoxylation of ketones and esters in 
the presence of sodium hydride (Swamer & Hauser, 1950) (Scheme 1).  
 
RCH2COY + NaH → Na(RCHCOY) + H2 
R’COOR” + Na(RCHOY) → R’COCHRCOY + NaOR” 
 
Scheme 1: Claisen acylation and carbothoxylation of ketones (Swamer & Hauser, 1950) 
The technique is regulated by a typical Claisen method whereby an acyl group is bound to a 
ketone. The reaction in general is valid for 1,3-diketones, ketoaldehydes and ketoesters 
having good yields (Swamer & Hauser, 1950) (Sambaiah et al., 2017) (Kel’in, 2003). Through 
intermolecular condensation, this technique produces good yield with methyl ketones and 
esters with the presence of metallic sodium. Modified procedures have been reported with 
the application of sodium methoxide and potassium tert-butoxide (Wai et al., 2000) 
(Nandurkar et al., 2007)  
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The Claisen-condensation of ketones and esters is also an efficient way of obtaining aliphatic 
and aromatic β-diketones (Nadurkar et al., 2007). This is because of its flexibility and milder 
environments in the method, it is commercially adapted in the synthesis of 2,2,6,6-
tetramethyl-3,5-heptanedione.  
3.1.2.1 Baker-Venkataraman Route 
Baker-Venkataraman has been one of the most efficient mechanisms in place to make β-
diketones and many classes of ‘natural-product-like’ compounds like flavones and chromones 
(Baker, 1933) (Gomes et al., 2009) (Lozano et al, 2012). This mechanism consumes o-
benzoloxyacetophenones undergoing base-catalysed intermolecular Claisen condensation of 
esters and ketones to generate o-hydroxydibenzoylmethanes (Ameen and Snape, 2015). This 
approach works well under microwave conditions as reported by Abdel Ghani and colleagues 
in 2008. With regards to the compounds synthesised in Procedure A, it has been suggested 
by Ares et al., (1993) to approach the methods using two ways. One of the variations to the 
method was suggested to be the addition of the hydroxyacetophenone and treat it with 2.2 
equiv of KOtBu. The benzoyl chloride was then added, and after heating, the diketone was 
obtained. The second variation looks more closely and parallels the 5-methoxyflavone 
synthesis. In this method, the hydroxyacetophenone was instead treated sequentially with 
1.1 equiv of KOtBu, the benzoyl chloride, and then a second 1.1 equiv of KOtBu. After heating, 
the diketone was isolated. 
A rapid method for the preparation of β-diketones is utilising a phenyl benzoate for 
dibenzoylation, which has been reported by Wallet and Gaydou (1996) as quite like the Baker-
Venkataraman mechanism. This was acknowledged as fast and efficient because there is no 
heating procedure necessary throughout the process (Fig 12).  







In Addition, substituted β-diketones (1-(2’,4’-dihydroxy- 5’ -chlorophenyl) 3-aryl-propane-1,3-
dione) have been produced by a speedy technique from acetophenones and aromatic acids 
to give the conforming benzoate, and with added dissolving in DMSO and sodium hydroxide 
followed by cooling in water (Sartape et al., 2015) (Sheikh et al., 2009)  
In 2005, Jae, Hwa and Mi developed a method carried out under argon starting with an 
acetophenone acid and a benzoyl cyanide as an alternative to an acyl chloride in the presence 
of lithium iso-propyl diamine (LDA) to produce the corresponding diketone with an excellent 
Figure 12 A modified mechanism of Baker-Venkataraman for the synthesis of β-diketones, highlighting ring closure 
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yield. The technique was also used to profit several β-diketone products with hydroxide, 
chloride and methoxy substitution (Salunkhe et al., 2015)  
O-hydroxy by-products of β-diketone are also produced by refluxing O-hydroxyacetophenone 
with aroyl chlorides in acetone and dry potassium carbonate. Methoxy substituents 
containing O-hydroxyacetophenones are treated with similar constituents with potassium 
hydroxide or potassium carbonate dissolved in benzene in the existence of a phase transfer 
catalyst. The same reacting materials irradiate within the microwave (at 80oC) and in the 
presence of 2 equivalents of DBU heated for 16 hours yield β-diketones in sufficient amounts 
(Ghani et al., 2008)  
A more efficient mechanism involves the development of the benzoate in pyridine starting 
from an acyl chloride. The produce is then heated at 26oC for 2 hours with potassium 
hydroxide, to obtain the desired diketone in good yield (Bansal, 2017)  
A parallel practise comprises of β-diketone in pyridine and crushed potassium hydroxide as a 
precursor to the synthesis of 3-benzoyl 6-methyl flavanone analogues (Haider & Haider, 2012). 
Despite this approach being simple and easy to formulate, the isolation of the compound from 
pyridine is a challenging task.  
Additionally, Sambaiah and colleagues in 2017, reported the first aromatic nucleophilic ring 
opening and ring closure (ANRORC) reaction for the synthesis of 3-benzoyl chromone with 
benzamidines. The technique adapts numerous β-diketone derivatives as a facile method to 
produce 3-benzoyl-4H-chromen-4-one. The condensation of 2-methoxyacetophenone with 2-
methoxymethyl benzoate in the presence of NaH, and the anhydride of 2-methoxy benzoic 
acid have reported to be ineffective in the synthesis of β-diketones (Jae et al., 2005) (Blaskó, 
Xun & Cordell, 1988).  
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A different methodology was adopted in the effort to counter the complications in chemo-
selective enolate formation of O- and C-acylated product of β-diketone. A series of bases and 
catalysts were used to investigate the efficacy of nitrogen heterocyclic carbene ‘NHC-




Figure 13 NHC stimulated synthesis of β-diketones (Singh et al., 2011). 
 
Oxidation of hydroxyketones produces the conforming β-diketones (Barlett and Beaudry, 
2011). Three oxidants have been studied; Dess-Martin-Periodinane (DMP), Swern oxidation 
and o-indoxybenzoic acid (IBX). The one to produce excellent yield was reported to be IBX 
compared to DMP and swern, accumulating poorer yield. Oxidation of alcohols to aldehydes 
and ketones with IBX has proven to be effective despite its poor solubility (More and Finnery, 
2002).  
An exceedingly regioselective and vastly yielding scheme gathering to about 98% for 1,3-
diketones using microwave aided synthesis entails using enol ether of acetophenone and 
benzoyl halides or benzoyl cyanide. The reaction time of 20 minutes is heightened in 
comparison to the conventional methods which involve 24 hours for accomplishment with 
undesirable by-products (Wiles, Watts, Haswell & Pombo-villar, 2002) (Fig 14). 
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Figure 14 Microwave-assisted production of β-diketone with silyl enol ether (Wiles, Watts, Haswell & Pombo-villar, 2002) 
 
3.1.3  β-Diketones as scaffoldings for different targets 
With the existing evolution in understanding the molecular foundation of cancer, attention 
has diverted to chemotherapy research that aims cancer through the diverse stages of its 
progression (Rayan et al., 2017). Over the past decades, different classes of compounds with 
diverse biological activity have been synthesised to inhibit cancer (Alam, 2018). Recently, non-
synthetic agents have been extracted as potential chemotherapy agents. β-Diketone is one of 
the compounds known to have antibacterial, antiviral and antitumour properties (Sheikh, 
Ingle & Juneja, 2009).  
A great quantity of β-diketone based compounds have been tested for cytotoxicity against 
tumour cells (Lin et al., 2011). Curcumin (Curcuma longa L) is acknowledged as one of the 
most common naturally occurring compounds and possess different bioactive properties such 
as antioxidants (Nakano et al., 2004).  
 
 
 Figure 15 Naturally occurring β-Diketone, Curcumin, which has been tested for 
potential anti-cancerous activity 
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An analogue of Curcumin, 1,3-diphenyl propane-1,3-dione has been reported as anti-
carcinogenic by conquering the growth of cells in various cell lines including COLO 205, A2549, 
HL-60, RAW 264.7 and HeLa. Results of some studies have directed that the β-diketone, 1,3-
propane-1,3-dione has a vastly potent activity and reduced the growth of mammary gland 
and uterine cells induced with 7,12-dimethylbenz[α]anthracene (DMBA) in mice (Miyata et 
al., 2001) (Sheikh et al., 2009). 
 
 
Figure 16 7,12-dimethylbenz[α]anthracene (DMBA) 
 
3.1.4 Keto Enol Tauterism 
Due to their structural orientation, mainly the presence of the two carbonyl groups which are 
separated by a methylene group (CH2), β-Diketones have more than a few other interesting 
properties (Urbaniak et al 2011). One interesting property arises as ketones and other 
carbonyl compounds have the presence of a hydrogen located adjacent to the carbonyl group, 
which in turn leads to the creation of a state of an equilibrium with a constitutional isomer 
called an enol, an unstable isomer. This conversation due to the acidity of the α-hydrogen on 
the carbonyl causes the phenomenon of a keto-enol interconversion or tautomerism, 
whereby two constitutional isomers are present in the equilibrium process. Distinguished 
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mainly by the positioning and location of the double bond from the Alkene group combined 
with the different bonding location of the labile hydrogen atom, these continuous rapidly 
interconverted isomers are known as tautomers, either keto or enol. Although the above is a 
reversible reaction, the keto form is usually said to be dominant over the enol form as seen 
by acetone which is 99.9% a keto tautomer, once a stable equilibrium has been achieved, the 
concentrations of the contained ketone and enol can be measured. It has been researched 
through these reactions that even within one-sided equilibria, the evidence for the presence 
of the minor tautomer comes from the chemical behaviour of the compound. 
As the equilibrium is the conversation of a parent keto form of a carbonyl containing organic 
molecule, either a ketone or aldehyde, into its enolic form, the process involves the transfer 
of a hydrogen atom or a proton from the α-carbon of the carbonyl to the carbonyl oxygen 
functional group, and is further accompanied by the saturation of the carbonyl double bond 
by an adjacent single bond. The said conversation above can be catalysed one of two ways, 
either via an acid or a base whereby the traces are generally present in most samples, with 
most papers referring to the keto-enol tautomeric equilibrium as an acid-base equilibrium. 
However, whether the catalysation is from an acid or base, a tautomerization process requires 
two main steps, protonation and deprotonation, but the order of these step is dependent 
upon the conditions the reaction takes place in. The acid catalysed keto-enol tautomerism 
starts off by the initiation of the protonation of the carbonyl oxygen atom, which then in turn 
activates the α-hydrogen/s. The result of the following steps results in one of the 
intermediates to lose one of the activated hydrogens thus yielding the enolic form of the 
compound. In comparison, the base catalysed keto enol tautomerism however starts the 
equilibrium process with the deprotonation of the acidic α-carbon to yield the enolate 
intermediate, which is then followed by the protonation of the carbonyl oxygen to again 
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produce the enol form. As the enolate form is described as resonance stabilized, the carbonyl 
compound is stated to be usually a much stronger carbon acid than is the alkene. An 
illustrative example of this is said to be of acetone, whereby the pKa is around 40 units smaller 
than the given literature pKa value of ethane. For both reactions, in most cases, the second 
step is much slower than the first step.  
It was previously mentioned above that the keto tautomer is much more dominant than the 
enol form, however Roger & Burdett (1965) say that owing to the presence of the less polar 
hydrogen atom which is located on the enol tautomer, this makes the mentioned form more 
favourable in inert solutions than the keto tautomer, which in contrast makes it much more 
dominant in polar solvents. Like the type of solvent used, there are many factors whereby 
which the balance of the equilibrium between a keto and enol form is affected. One major 
factor described by Cook et al., (2007) & Smith et al., (2016) which shifts the balance of 
equilibria between the tautomer’s is said to be the potential substituents attached to the 
carbonyls and the shift is dependent on the nature of the substituting group. In addition, even 
though a carbonyl group is much more fundamentally stable than a converted enol group, the 
presence of other functional groups, due to the rise of additional stabilization effects, can 
shift the balance of the equilibrium state from the much more dominant keto form to favour 
the enol form. A prime example of this concept coming to light is of Phenol, an aromatic 
organic compound consisting of a phenyl group to a hydroxy group, which is predominately 
much more stable than its corresponding keto tautomer, 2,4-cyclohexadienone, due to the 
basis of its aromaticity. The same concept has been found to be true for Dibenzoylmethane, 
which has been mentioned to exist exclusively in an enol form, which is chelated by an 
intramolecular hydrogen bond. Furthermore, other factors found to shift the balance of 
equilibria in research from the keto form to the enol form, or vice versa include electron 
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withdrawing/donating groups, steric effects and temperature. Another important factor 
mentioned is due to a natural/physical property rather than chemical. As a rapid 
interconversion shifts the balance continuously, the tautomeric equilibria in the excited state 
of a compound can be very different than those which exist simultaneously within the ground 
state. Furthermore, in many cases which have been researched, it has been possible to induce 
an isomerisation between two existing tautomeric forms by light. Naumov and co-workers 
have recently applied the usage of time-resolved emission spectroscopy to highlight that the 
concept of photoexcitation can successfully induce the enolization of the given keto form of 
6’-dihydroxyoxyluciferin. This is also in addition to the research conducted by Yankov et al., 
(2004), who have exclusively shown in their work that the keto form of Dibenzoylmethane, 
found to be relatively unstable in the ground state, is formed via the process of 
photoexcitation.  
Even though the equilibria between a keto and enol form is rapid and can be measured 
through acid/base reactions, the effect can be identified in most of the NMR results and 
spectra, whereby the region of peaks at 190 ppm are attributed to the ketonic carbon, and 
the peak at 175 ppm for the enolic carbon (Abdel Ghani., 2008). The following values are only 
for 13C NMR. 
 
Figure 17 The equilibrium balance formed between the Keto and Enol Tautomer during rapid excitation 
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3.2 Biological Evaluation  
 The in vitro biological activity and pharmacological parameters of the synthesised 
compounds was assessed using a series of various assays. The first biological evaluation 
studied the cytotoxic ability of the drug candidates to determine growth inhibition of the cells 
using the MTT assay. Cisplatin, a chemotherapy medication used to treat several cancers, was 
used as a standard in order to enable the obtained data to be compared to that of an existing 
anti-cancer agent within literature. Following this, pharmacological parameters measuring 
the stability of the candidates, within different concentrations of Plasma and then S9 fraction 
over time were analysed using HPLC. Rifampicin, a semisynthetic macrocyclic antibiotic, was 
used as a standard control in order to determine data values such as % Compound remaining, 
t1/2 and CLint. The pharmacological studies were conducted on a preliminary basis since a 
standard control was only used and no positive control compound, which was known to be 
unstable within the conditions tested. 
 
3.2.1 Cytotoxicity – MTT Assay 
The library of synthesised potential drug candidates was first screened using the MTT assay; 
with the anticancer activity of all the compounds of interest being tested on adherent in vitro 
cancer cell lines. The assay used allows for the determination of the half maximal inhibitory 
concentration (IC50), which effectively shows the required concentration of dose needed in 
order to inhibit the growth of cells by 50%. He and peers (2016) state that the determination 
of the IC50 value is essential to understand the pharmacological and biological characteristics 
of a chemotherapeutic agent. 
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There are several assays available to determine cytotoxicity of available and newly formed 
compounds. First described by Mosmann in 1983, the usage throughout in vitro studies of the 
yellow tetrazolium salt, 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide, or 
more commonly known as MTT, as an indicator for the viability of cells and their proliferation 
has increased. A traditional method for anti-cancer drug discovery and classical method for 
screening cytotoxic anti-cancer agents, the assay method is used widely to determine 
cytotoxicity, proliferation and activation of potential medicinal agents on the activity of 
mitochondrial dehydrogenase enzymes in cells (Scherliess, 2011). In addition, uses can also 
help evaluate cytotoxicity potential of drugs carried by liposomes (Angius and Floris, 2015). A 
liposome represents multipurpose drug delivery system to administer drugs, whereby the 
system can undergo the process of alteration by either varying the size, lipid composition, 
electrical charge, membrane fluidity and finally the conjugation with surface-coating layers 
(Manconi et al, 2007). More specifically to cancer, it has been reported to be used to screen 
cytotoxic compounds during the development of chemotherapy or also to screen for 
unwanted cytotoxic effect during preclinical trials (Scherliess, 2011). The ease of the 
methodology, coupled with the speed at which results are obtained, makes MTT assays a 
useful operator-independent method for studying the number of cells (Lui, 2009). However, 
Hansen et al (1989) reports that since the formation of the test by Mosmann, it has been 
modified several times since.  
MTT works on the principle that only viable cells have the ability to reduce a yellow aqueous 
solution, which is given by MTT, and convert it into Formazan, described as a dark purple-
violet colour, which is strongly lipophilic and water insoluble. This therefore can be detected 
colour metrically and the photometric assessment of the formazan concentration accounting 
for the number of viable cells (Van Meerloo et al, 2011). Fotakis and Timbell (2006) state 
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‘Viable cells are able to reduce yellow MTT under tetrazoliumm ring cleavage to a…Formazan 
which precipitates in the cellular cytosol, whereas dead cells after damage, cannot transform 
MTT’. It was widely the concept that the amount of MTT formazan is directly proportional to 
the number of living cells (Van Meerloo et al, 2011), however according to Etxeberria et al 
(2011) this conclusion has now been seriously question. 
Lui (2009) writes that the principle premise of the assay is the intrinsic ability of mitochondrial 
dehydrogenases and other reducing agents present in metabolically active cells to reduce the 
MTT compound. In addition, further research has provided biochemical evidence to indicate 
that MTT is mainly reduced in the cytoplasm of cells by NADH and other dehydrogenases 
associated to the endoplasmic reticulum (ER) (Berridge et al, 2005).   
Even though the use of this assay is common, the technique does have several flaws to it. Lui 
(2009) states that the reduction of MTT may not be entirely dependent upon the number of 
cells but also upon the mitochondrial function and proliferation state. Results have shown an 
underestimation of cell numbers when the cells which have been studied are positioned in 
such a manner. These may be positioned towards the upper end of the growth curve, where 
factors such as high cell densities and sub-optimal growth conditions would in turn hinder 
endogenous enzyme function. Further to this statement it says that since MTT values are 
attained from cells treated with drugs, then usually compared with results of those left 
untreated, it most likely will be the case that the action of  the drug studies maybe over-
estimated. Normally another case for this is that fact that since the MTT assay is based on the 
reduction reaction of dyes resulting in colour changes, as the reduction is mediated 
enzymatically, other reduction substances still have the ability to interfere, as mentioned by 
Madesh and Balasubramanian (1998) where the effectors were stated to be Reactive Oxygen 
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Species (ROS). In addition, research by Soenen and De Cuyper (2009) state other reduction 
process induced by liposomal preparations may affect the MTT assays. This was found by 
Angius and Floris (2015), where their study showed a direct interference of liposomes within 
the MTT assay, where observed cells treated with liposomes showed higher MTT absorbance 
values than the control used. In conclusion, Simms and Plattner (2009) concluded their study 
stating that the usage of the MTT assay was an inappropriate method for the means of testing 
the activity of drugs used for solid tumours. 
3.2.2 Cell Lines 
The following cancer cell lines were used to screen the compounds; A549, Caco-2, HCT-116, 
HeLa and HepG2, with the incubation periods set as; 24, 48, 72 and 96 hours. The 
concentration dose range for all compounds whereby at the time of testing was; 3.125µM, 
6.25µM, 12.5µM, 25µM, 50µM and 100µM.  
3.2.2.1 HepG2 
Renowned as one of the most widely used cell lines for the application of evaluating the 
toxicity of chemicals and drugs alike, is the human hepatocellular carcinoma cell line, HepG2. 
Known to possess 55 pairs of chromosomes with the ability to be grown successfully at a large 
scale and secrete various plasma proteins such as fibrinogen, transferrin and albumin, these 
cells are said to be adherent and epithelial like. HepG2 cells are conventionally cultured as a 
form of monolayer in a two-dimensional (2D) culture plate in small aggregates, stimulated 
with the aid of human growth hormones, which provides them with a doubling time of around 
48 hours.  
HepG2 cells were obtained from the biobank at the University of Salford, and sub-cultured as 
per the protocol in order to be used as required. The cell line is derived from the liver tissue 
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of a Caucasian American, aged 15 (Gerets et al., 2012). Originally established in 1979 by 
Barbara Knowles and fellow colleagues, HepG2 has been reported as a hepatocellular 
carcinoma (Aden et al 1979). As mentioned, HepG2 cells were subcultured every two to three 
days and grown in RPMI-1640 medium (biosera) supplemented with FBS (10%), penicillin (100 
units/mL), streptomycin (100µg/mL) and L-glutamine (2mM). 
3.2.2.2 HCT-116 
Defined as a human colon cancer cell line, HCT 116 cells are found to be one of three 
colorectal carcinoma subpopulations from a single male human. The cell line is commonly 
used to study the biology of cancer due to its nature, whereby it is a growth factor 
independent cell line with a relatively low doubling time of approximately 21 hours. Although 
many researchers recommend the usage of McCoy’s 5A medium for the growth of HCT 116 
cells, various publications have suggested that HCT cells can efficiently grow in RPMI-1640. 
Therefore HCT 116 cells were grown in RPMI-1640 medium (biosera) supplemented with FBS 
(10%), penicillin (100 units/mL), streptomycin (100µg/mL) and L-glutamine (2mM). In addition, 
the cell line is said to be highly aggressive human colorectal cell line with no known ability to 
differentiate and no expression of caudal type homeobox 1 (CDX1) coding gene. CDX1 is 
responsible for gene expression regulation such as that of intestinal alkaline phosphatase 
gene, which is responsible for dephosphorylation, and the inhibition of beta-catenin 
transcriptional activity, which is involved in cell adherence and gene transcription. It is also 
important in the differentiation of enterocytes (Yeung et al., 2010). 
3.2.2.3 HeLa 
Obtained from the European Collection of Cell Cultures, the HeLa cell strain was first extracted 
from an epidermoid carcinoma of the cervix by George O. Gey from a patient named Henrietta 
Lacks in 1951 (scherer & Syverton, 1952). Defined in science as an ‘immortal’ cell line, 
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whereby it was the first strain to be grown successfully within cell culture laboratories, it is, 
along with HepG2, the most commonly used till date due to its proficient, durable and prolific 
properties. The endothelial cell monolayers provide another quick doubling time of 24 hours, 
with HeLa cells typically sub-cultured every two days, and grown in RPMI-1640 medium 
(biosera) supplemented with FBS (10%), penicillin (100 units/mL), streptomycin (100µg/mL) 
and L-glutamine (2mM). 
3.2.2.4 A549  
A549 cells were obtained from the University of Salford. Typically grown as a monolayer, the 
adherent and epithelial like cell is derived from the lung. The cell line was first isolated in the 
year 1973 from a pulmonary adenocarcinoma, which is the removal and culture of cancerous 
lung tissue by D.J Giard and his team. Although A549 cells are a representative of the Alveolar 
type II pneumocyte of the human lung, the strain was deprived from a 58-year-old male 
Caucasian and used for their speedy doubling time of approximately 22 hours. Again, the A549 
cells were grown in RPMI-1640 medium (biosera) supplemented with FBS (10%), penicillin 
(100 units/mL), streptomycin (100µg/mL) and L-glutamine (2mM). 
3.2.2.5 CaCo-2 
The Caco-2 cell line is a differentiated cell line originally collected from a human, adult colon 
adenocarcinoma. They express cylindrical polarised morphology, tight junctions between 
adjacent cells and express hydrolase enzymes (Sambuy et al., 2005). The cells were grown in 
RPMI-1640 medium (biosera) supplemented with FBS (10%), penicillin (100 units/mL), 
streptomycin (100µg/mL) and L-glutamine (2mM). 
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3.2.3 Cytotoxicity – Cisplatin 
Following on, Cisplatin was used as a basis for the comparison of the potential drug candidates, 
since the anti-cancer agent has been tested on various cell lines, which are mentioned in 
literature. IC50 values for the required cell lines were calculated as shown in Table 2 and then 
plotted as per Figure 18. 
Table 2 IC50 values calculated for Cisplatin. Cytotoxicity was observed on HepG2, HeLa, HCT-










Cell Line IC50  [µM] 
Cisplatin 
24h 48h 72h 96h 
HepG2 8.54 ±1.54 7.26 ±1.89 5.89 ±2.42 5.37 ±1.05 
HeLa 7.72 ±1.69 6.57 ±1.96 5.71 ±2.54 4.53 ±2.47 
HCT-116 10.30 ±2.94 8.49 ±1.89 6.64 ±2.54 5.63 ±1.65 
A549 11.23 ±1.54 9.11 ±1.23 7.31 ±1.28 6.04 ±2.41 
Caco-2 9.27 ±2.39 7.97 ±2.87 6.78 ±2.69 5.75 ±1.04 
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Figure 18 A graph showing the % Cell Viability of Cisplatin when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 
6.25uM 
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3.2.4 Cytotoxicity - DBM and Derivatives (Compounds 1-10) 
Tested in triplicates and over a period of 96 hours, the β-diketone derivatives showed an 
overall positive effect on all the cell lines which were used for screening. The general 
observation found was that as the incubation period increased, the average IC50 values 
decreased, thus suggesting that as time progressed, cells which were treated were gradually 
destroyed.  
Using the values from tables 3-5, a combined estimated average for the IC5o values at the 
different incubation periods, 24h,48h,72h and 96h, could be calculated for all the β-diketone 
derivatives, and confirmed the theory that results obtained from the MTT assay were time 
dependant. As observed, the derivatives at the 24h incubation period for all cell lines had an 
average IC50 value range from between 18.20µM to 27.81µM, whereby the range values 
decreased between 14.45µM – 21.27µM for the incubation period of 48hr. The IC50 value 
range calculated for 72hr was 12.92µM – 19.09µM followed by 11.79µM – 19.00µM for 96hr, 
an apparent decrease over time. It has been known that a low IC50 value is a positive 
characteristic of a potential drug candidate, whereby the low concentration threshold of the 
dose is seen a more potent.  
 
Table 3 IC50 values of Beta-Diketone derivatives. Cytotoxicity was observed on HepG2 and 
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Compound IC50  [µM] 
HepG2 HeLa 
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Table 4 IC50 values of Beta-Diketone derivatives. Cytotoxicity was observed on A540 and 
HCT-116 cell lines, with the standard deviation being calculated based on triplicate results 
 
Compound IC50 [µM] 
A549 HCT-116 

















































































































































































106 | P a g e  
 
Table 5 IC50 values of Beta-Diketone derivatives. Cytotoxicity was observed on the Caco-2 



















Compound IC50 [µM] 
Caco-2 

























































































107 | P a g e  
 
Using the graphical plots for Log Concentration vs Cell viability, calculated IC50 values 
highlighted that no β-diketone derivative was more effective than Cisplatin on any of the cell 
lines. It was noted however that the candidates which were screened did show positive 
potency effect on some cell line better than others. To start off with, DBM, which is commonly 
used in sunscreen and was used as an initial starting sub-structure for the derivatives 
displayed a steady response to all cell lines. It was seen that after the 24hr period, the effect 
of DBM in terms of IC50 values shows a significant drop, which positively indicates a cytotoxic 
effect overall. Across all cell lines, the compound displayed a drop of around 10µM in terms 
of concentration for given IC50 values. This can be seen on the HepG2 cell line were the IC50  
value for the 24hr incubation period of the cells studied was 23.30µM but dropped to 
11.76µM at 96h, the same being seen for A549 and HCt-116, where the decrease was from 
24.44µM to 13.27µM and 18.28µM to 11.30µM respectively.  
When DBM was altered in order to provide the compounds 1 & 2, which contain extra 
Hydroxyl (-OH) groups at different aromatic positions, a difference in cell viability and IC50 
values was displayed across the cell lines. As before, IC50 values after the 24-hour incubation 
period show a substantial response in terms of decrease, as exhibited by compound 1 on the 
HepG2, HeLa and A549 cell lines. Values from Table 5 show that at the 24hr incubation phase, 
the IC50 values were 27.04µM. 33.17µM and 24.75µM, all higher than that of DBM. However, 
as the gradual treatment of the cells progressed over time, the values calculated at time 96hr 
were 14.54µM, 14.90µM and 10.23µM. An important thing to note in this finding is that bar 
one, all the IC50  values of compound 1 after 96hr were found to be lower than that of DBM, 
thus suggesting that initially there may be a scope for delayed activity but the overall potency 
of the compound candidate in much greater over time. The same concept in terms of findings 
can be stated for compound 2, however once observed closely on individual cell lines, data 
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values indicate a proximity between the IC50 values at 72hr and 96hr for the HepG2 and HeLa 
cell lines. It seems like a plateau has been reached and no further cytotoxic effect will take 
place without a strong increase in dose concentration. The values which show this are as 
follows; HeLa - 9.34µM & 9.12µM, HepG2 – 11.20µM & 10.46µM.  
Graphs showing the concentration vs cell viability at different time points across the cell lines 
can be seen in Figure 19-21 for DBM and compounds 1&2. As stated previously, as increase 





Figure 19 A graph showing the % Cell Viability of DBM when tested on all 5 cells lines, which include HepG2, HeLa, HCT-116, A549 and 
Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM 
and 3.125uM 




Figure 20 A graph showing the % Cell Viability of Compound 1 when tested on all 5 cells lines, which include HepG2, HeLa, HCT-116, A549 and 
Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM and 
3.125uM 








Figure 21 A graph showing the % Cell Viability of Compound 2 when tested on all 5 cells lines, which include HepG2, 
HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and dosed at 
concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM and 3.125uM 




Figure 22 A graph showing the % Cell Viability of Compound 3 when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
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Figure 23 A graph showing the % Cell Viability of Compound 5 when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 
 
When compounds 3 (Fig 22) & 5 (Fig 23) were investigated across all the cell lines, it was 
apparent that chemical substitution and position of functional groups plays a big role in the 
potency of the compounds to exhibit a form to cytotoxicity. To the general substructure of 
DBM, compounds 3 & 5 both contained the Hydroxyl (-OH) group at the Ortho position of the 
aromatic ring, however the relative substituents were positioned at the Meta (Cl) and Para (-
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OCH3) respectively. Compared to compound 5, compound 3 initially shows a low IC50 range 
between its values, with the greatest range being 8µM for the A549 cell line. On the other 
hand, the greatest range found for compound 5 was 16µM on the HepG2 cell line, an amount 
nearly double that of compound 3. Overall the compounds follow the pattern discussed above 
of a time dependant response, however the response observed by compound 5 is said to be 
more rapid than that of compound 3. From the results, it can be deduced that both the 
compounds exhibit better cytotoxic effects than DBM on the HepG2 and HeLa cell lines, 
whereby the IC50 values after 96h are in the low spectrum of values, however the response 
is not immediate, rather steady then rapid. As seen from compounds 1 & 2, the presence of 
the OH group plays a role in the IC50  values being low, however it can be seen that the 
presence of a halogen group initially provides the platform for the compounds to have an 
immediate effect whereby the IC50  values at 24h of the incubation period were lower than 
those exhibited by DBM, compound 1, 2 & 5 at all the cell lines bar one. Following this, the 
addition of a methoxy group in place of a halogen indicate that the functional group rather 
helps with the response exhibited over time than that off an immediate response. Comparing 
the values of compound 5 with 1 & 2, it was observed that a higher initial IC50 value at 24h 
had decreased by a significant amount at 96h. This is shown where the IC50 of compound 5 
has been at 25.13µM (HepG2) and 28.20 µM (A549) but decreased to 9.86µM (HepG2) and 
13.92µM. The data values were observed from 5-7 
Furthermore, the concept of a carbon or oxygen related group such as a Methyl or Methoxy 
to stabilise the compounds in order to exert their cytotoxic effects has further been 
strengthened by the findings of compound 4 being screen, in direct comparison with DBM. A 
very similar structure to that of DBM, compound 4 contains a bromine group, a halogen, 
attached to the central carbon between the 1,3 diketone, which understandably has replaced 
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the -CH2 group. Findings have shown that the compound which contains the Br substituent 
has on average higher IC50 values than DBM at the 96h incubation phase.  This indicates that 
the presence of a group other than Oxygen or Carbon on the central carbon atom hinders the 
prospect of a compound exerting its cytotoxic activity. However, it is to be noted that 
compound 4 did have a better cytotoxic effect and potency on the Caco-2 cell line, a potential 
candidate for cancer effecting the colon since initial (24h) and final (96h) IC50 values were 














Figure 24 A graph showing the % Cell Viability of Compound 4 when tested on all 5 cells lines, which include 
HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and 
dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM and 3.125uM 
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The graphs for compound 4 (Fig 24) highlight that the target compound maybe rendered 
unfavourable in contrast to other β-diketone derivatives tested. However, it should not be 
classed that the addition of halogen/s or related groups be counted out as unfavourable, since 
many derivatives work and exert their effects on one cell line but struggle to initiate a 
response against another. This was the case when compounds 7 & 8 were tested on the cell 
lines. Both compounds contain a Fluorine group substituted on the benzene aromatic ring, 
alongside bulky methoxy groups. Initially on the HepG2 and HeLa cell lines, it was seen that 
the compounds documented low IC50  values, 11.13µM and 13.13µM (HepG2 at 24h) & 
16.33µM and 15.81µM (HeLa at 24h) decreasing to 8.06µM and 9.31µM (HepG2 at 96h) & 
11.57µM and 11.54µM (HeLa at 96h), however when screened on the other cell lines such as 
HCT-116, a cell line where other derivatives including compound 4 showed an IC50  range of 
between 8.78µM – 18.43µM, the compounds in question displayed starting IC50  values of 
48.50µM & 48.17µM (24h) and final values of 35.49µM & 34.02µM (96h). These values were 
calculated to be the highest obtained for any β-diketone derivative.  
The range of IC50 values for compounds 7 & 8 can be seen in Fig 26-27. Even though high 
values have been calculated for the compounds, they have still shown to exert a cytotoxic 
effect on the tested cells.  
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Figure 25A graph showing the % Cell Viability of Compound 6 when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
















Figure 26 A graph showing the % Cell Viability of Compound 7 when tested on all 5 cells lines, which include HepG2, 
HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and dosed at 
concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM and 3.125uM 




Containing methoxy groups in various positions on the aromatic ring, compounds 9 (Fig 28) 
and 10 (Fig 29) displayed properties which highlight their cytotoxic effect but also, for the first 
time in this investigation of β-diketone derivatives, a proliferation effect was seen. Even 
though the difference between both compounds is that 10 contains ether groups on one 
aromatic ring, whereas 9 has them present on both aromatic rings, a potent cytotoxic effect 
followed by a proliferating effect was observed on the HCT-116 cell line. This was observed 
after a significant response was registered from the 24h to 72h incubation period, however 
at 96h, the increase in IC50 values show the effect as either cytostatic or degradation and 
metabolism were causing a reduction if efficacy. The increase in IC50 values were from 
15.88µM and 15.08µM at 72h to 28.07µM and 18.00µM at 96h. From this, compound 9 which 
Figure 27 A graph showing the % Cell Viability of Compound 8 when tested on all 5 cells lines, which include HepG2, HeLa, HCT-116, 
A549 and Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 
12.5uM, 6.25uM and 3.125uM 
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contains a trimethoxy on each aromatic ring, shows a double increase in the IC50 values, 
12.19µM when compared to compound 10, which contains trimethoxy groups on one 
aromatic ring. The increase in IC50 value seen here was 2.92µM.  
 
 
Figure 28A graph showing the % Cell Viability of Compound 9 when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 
 





Figure 29 graph showing the % Cell Viability of Compound 10 when tested on all 5 cells lines, 
which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 
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The tests on the β-diketone derivatives do indicate and confirm that the cytotoxic effect of 
the compounds on the cell lines is time and concentration dependant, whereby the potency 
of the candidates is found to be at concentration dose levels around the 17µM - 25µM mark. 
Moreover, no candidate was found to have a better effect on the cell lines than the internal 
control of Cisplatin.  
3.2.5 Cytotoxicity - 2-Azido Derivatives (Compounds 11-13) 
Calculated IC50 values (Table 6-8) across all cell lines for the 2-Azido-diketone derivatives 
show the maximal dose required for 50% cell growth inhibition to be between the range of 
16µM and 47µM. The values calculated were found to be higher than those of the β-diketone 
derivatives, especially DBM, 1 and 3, since the synthesised 2-Azido derivatives were based on 
a similar substructure. Like the β-diketones, the compounds did display a time dependant 
activity whereby the IC50 would decrease over the time period as seen within Figures 30- 32, 
however the significance in response was seen to more than double. Compounds which 
exhibited effective cytotoxic potency was 11, on the HCT-116 cancer cell line. With a IC50 
concentration of 16.57µM at 24h, over time the value decreased at 96h to 12.34µM, a small 
but effect drop in terms of potency. Compounds 12 & 13, combined with 11, displayed steady 
decreases in IC50 over the 24h-96h incubation treatment period, and changes in values did 
not exceed a 10µM range.  
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Table 6 IC50 values of 2-Azido-Diketone derivatives. Cytotoxicity was observed on HepG2 
and HeLa cell lines, with the standard deviation being calculated based on triplicate results. 
 
Table 7 IC50 values of 2-Azido-Diketone derivatives. Cytotoxicity was observed on A540 and 
HCT-116 cell lines, with the standard deviation being calculated based on triplicate results 
 
Compound IC50  [µM] 
HepG2 HeLa 

















































Compound IC50  [µM] 
A549 HCT-116 
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Table 8 IC50 values of 2-Azido-Diketone derivatives. Cytotoxicity was observed on the Caco-2 











Compound IC50  [µM] 
Caco-2 
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Figure 30 A graph showing the % Cell Viability of Compound 11 when tested on all 5 cells 
lines, which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at 











Figure 31 A graph showing the % Cell Viability of Compound 12 when tested on all 5 cells 
lines, which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at 










Figure 32 A graph showing the % Cell Viability of Compound 13 when tested on all 5 cells 
lines, which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at 
periods of 24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 
12.5uM 
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3.2.6 Cytotoxicity on Benzoylurea Derivatives (Compounds 14-16) 
The cytotoxicity of benzoylurea derivatives was determined in contrast to β-diketone with an 
interest to see what the C=S bond within the compound instead of the C=O carbonyl bond 
will provide with regards to cytotoxic effect. The benzoylureas were screened on all the cell 
lines as before and over the same time period with the same concentration doses. It was 
found that the benzoylurea derivatives exhibited an aggressive response to that off the β-
diketones in terms of expressing IC50 values, as some cell lines displayed very high IC50 values 
which dropped rapidly over time.  Nearly all the IC50 values calculated were shown to be over 
30µM except for the A549 cell line, which may suggest Benzoylurea derivatives to inhibit 
growth on breast cancer. This was shown where the IC50  values of compounds 14 (26.50µM), 
15 (25.74µM) and 16 (26.18µM) at 24h and then at 96h, 17.66µM (14), 17.39µM (15) & 
13.26µM (16) were calculated, ranges which were associated to the β-diketones.  
It can be suggested that the Benzoylurea derivatives work better on an immediate basis, since 
the drop in IC50 after 24h was such a significant response. 
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Table 11 – IC50 values for the Benzoylurea derivatives. Cytotoxicity was observed on HepG2 
and HeLa cell lines, with the standard deviation being calculated based on triplicate results. 
 
Table 12 IC50 values for the Benzoylurea derivatives. Cytotoxicity was observed on A549 and 
HCT-116 cell lines, with the standard deviation being calculated based on triplicate results. 
 
Compound IC50  [µM] 
HepG2 HeLa 

















































Compound IC50  [µM] 
A549 HCT-116 
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Table 13 IC50 values for the Benzoylurea derivatives. Cytotoxicity was observed on the Caco-











Compound IC50  [µM] 
Caco-2 





































Figure 33 A graph showing the % Cell Viability of Compound 14 when tested on all 5 cells lines, which 
include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at periods of 24, 48, 72 and 96 
hours, and dosed at concentrations; 100uM, 50uM, 25uM, 12.5uM, 6.25uM and 3.125uM 




Figure 34 A graph showing the % Cell Viability of Compound 15 when tested on all 5 cells 
lines, which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at 










Figure 35A graph showing the % Cell Viability of Compound 16 when tested on all 5 cells 
lines, which include HepG2, HeLa, HCT-116, A549 and Caco-2. Cells were incubated at 
periods of 24, 48, 72 and 96 hours, and dosed at concentrations; 100uM, 50uM, 25uM, 
12.5uM 
The cell lines were selected to provide examples of several common tumour types in order to 
determine if the compounds exhibited cell line specific action or lead to consistent growth 
inhibition across multiple lines. It was found that activity was structurally and cell line 
dependent 
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3.3 Plasma Stability Assay 
One of the most challenging tasks in drug discovery is predicting the pharmacokinetic 
behaviour of a new chemical entity (NCE) in humans using data derived from in vitro model 
systems. 
Conducted on over 200 top oral products a study revealed that an estimated 37% of drugs 
had very low solubilities, some less than 0.1mg/mL. The issue of poor solubility is one of the 
most important and common problems faced by scientists during the drug development 
phase. However, properties which give rise to these undesirable characteristics such as poor 
aqueous solubility, chemical instability, low half-life, toxicity and fast metabolism can be 
solved, and require the use of the prodrug approach. These are pharmacologically inactive 
compounds which can be readily converted in vivo to the active form, either enzymatically or 
nonenzymatically in order to exert their therapeutic effect. The term stability refers to the 
capacity of the drug to remain unchanged throughout time, and the effects can be studied 
under various environmental conditions such as light, temperature and chemical 
environment. The definition given by Skopp et al (2004) is, “capability of a sample material to 
retain the initial value of a measured quantity for a defined period within specific limits when 
stored under defined conditions.”  Or “the chemical stability of an analyte in a given matrix 
under specific conditions for a given time interval.” (Shah et al, 1992). However, in 
pharmaceutical principles, stability looks at the storage time allowed before any degradation, 
which can be expressed scientifically as shelf life. In addition, Stability can be determined 
through the continuous monitoring of the concentration of the analyte, be it in a stored 
solution or biological sample.  
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Von rauch et al (2004) mention that during the initial drug discovery stage, when a potential 
drug candidate is screened against any biological targets, the compounds in question need to 
display sufficient stability in the assay buffers for enzyme, receptor or even cell-based assays 
in order to reliably measure any form of biological activity. Plasma stability has been known 
to play an important role in the drug discovery and development phase, since it has been 
highlighted that rapid metabolism will lower the exposure a drug exhibits at the therapeutic 
targets, and combined with the instability of a compound, difficulties in obtaining accurate in 
in vitro studies increases since such molecules continue to degrade even after samples have 
been evaluated. Within the human body, there are various ways a drug is broken down, and 
the metabolism of a drug or metabolite can occur in blood cells or within the fluid composites 
of blood itself, such as serum or plasma. Plasma is the largest part of blood, since it makes up 
more than half (~55%) of its content. Separated from blood as a light-yellow liquid, it mainly 
contains function water (~90%), salts and enzymes. Antibodies, clotting factors in addition to 
other biological matter such as nutrients, hormones and proteins (albumin and fibrinogen) 
are circulated too. Other components which can be easily carried or transported are drug 
metabolites, either in their pure, active or inactive forms. The process of metabolism, 
whereby the compound is broken down, can be referred to as metabolic instability, which is 
unique to the biological matrices, chemical instability due to the inherent properties of a 
compound such as oxidation, hydrolysis or isomerization. It has been studied that compounds 
with specific functional groups are more susceptible to these metabolic reactions then others. 
The main groups are the following esters, amides, lactones, lactams, carbamides, 
sulphonamides, and these are more favourable targets for plasma enzymes such as 
hydrolases and esterase.  
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Since these functional groups are contained within the class derivatives synthesised, the 
plasma stability assay will investigate the effects of this and calculate the percentage of test 
compound remaining over how much has been degraded.  
The plasma stability assay was conducted as a triplicate, whereby the conditions analysed the 
degradation of the potential drug candidates over a period of 120 mins. Conditions utilised 
by the assay included the usage of an internal control, Rifampicin, the temperature of the 
water bath at 370C in order to replicate the human body, and the concentration of the plasma 
used at 50% and 100% respectively.  The assay determines the stability of the new chemical 
entities in plasma vital since this will indicate the level of in vivo efficacy. Compounds were 
subjected to the plasma stability assay in order to determine the percentage of test 
compound remaining over different time intervals. Plots were visualised to show the 
difference in compound degradation for each synthesised candidate, and thus compared to 
RMP, which is stated to be relatively stable in a neutral pH of 7.4. Another control, whereby 
no plasma was present was also utilised for data analysis. Since a known compound which is 
unstable within these conditions was not used as a positive control, the data is presented 
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Table 14 Containing the data obtained from all compounds when tested at conditions 
containing 50% Plasma concentration, incubated over time intervals from 0 – 120 minutes. 
Data highlights % compound remaining from 100% and an overall % decrease from first 
incubation to last.  
Compound 






0 5 15 30 45 60 120  
RMP 100 98.7 96.6 94.4 91.7 87.9 84.1 15.9 
DBM 100 98.1 90.3 84.3 80.2 75.6 69.2 30.8 
1 100 98.5 93.4 90.3 86.8 81.6 75.8 24.2 
2 100 98.9 95.3 91.4 87.6 83.6 78.9 21.1 
3 100 96.7 92.5 90.8 86.3 81.7 73.5 26.5 
4 100 94.6 89.3 86.1 80.2 74.3 68.7 31.3 
5 100 97.4 92.7 88.3 84.1 79.2 73.1 26.9 
6 100 95.7 89.3 81.2 76.2 73.6 69.9 30.1 
7 100 94.1 89.4 81.3 74.6 68.3 64.3 35.7 
8 100 95.1 90.3 80.6 75.2 67.3 63.9 36.1 
9 100 92.1 87.3 78.3 71.2 64.3 62.8 37.2 
10 100 91.5 88.3 79.1 71.4 65.2 63.0 37.0 
11 100 84.1 73.5 66.5 59.4 50.1 46.3 53.7 
12 100 88.9 79.2 72.5 64.3 57.2 50.7 49.3 
13 100 86.2 77.3 70.8 62.3 55.6 49.1 50.9 
14 100 98.2 97.1 93.2 90.3 86.1 82.3 17.7 
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15 100 98.6 96.4 92.3 91.3 84.3 80.1 19.9 
16 100 97.6 95.3 91.5 91.3 83.6 81.2 18.8 
 
Table 95 Containing the data obtained from all compounds when tested at conditions 
containing 100% Plasma concentration, incubated over time intervals from 0 – 120 minutes. 
Data highlights % compound remaining from 100% and an overall % decrease from first 
incubation to last. 
Compound 






0 5 15 30 45 60 120  
RMP 100 97.7 95.6 91.2 87.6 84.3 82.4 17.6 
DBM 100 93.7 86.7 81.3 74.6 69.2 62.3 37.7 
1 100 94.1 91.6 84.5 78.3 71.8 65.6 34.4 
2 100 94.8 92.4 87.6 81.3 75.8 68.3 31.7 
3 100 92.6 90.4 82.3 76.8 70.1 64.2 35.8 
4 100 82.3 79.4 69.2 58.3 55.6 50.2 49.8 
5 100 94.2 90.3 83.4 76.3 70.8 63.4 36.6 
6 100 93.1 86.2 79.3 71.2 67.8 59.3 40.7 
7 100 92.1 86.5 78.3 71.3 64.2 59.1 40.9 
8 100 91.9 85.4 79.3 72.4 64.6 60.3 39.7 
9 100 90.1 84.3 74.2 69.2 60.2 56.2 43.8 
10 100 91.2 86.1 75.2 69.4 61.3 56.2 43.8 
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11 100 78.3 65.3 52.7 43.1 35.8 28.3 71.7 
12 100 83.6 70.5 61.3 52. 44.9 37.8 62.2 
13 100 81.3 68.2 59.4 50.9 42.1 35.6 64.4 
14 100 96.3 94.2 92.3 88.3 82.1 79.3 20.7 
15 100 95.3 93.4 91.2 86.1 81.3 79.2 20.8 
16 100 96.3 91.2 89.6 84.6 81.8 80.3 19.7 
 
The values from tables 14-15 highlight that fact that when the plasma concentration is higher, 
the percentage of compound degradation is also much higher. This correlation factor is 
evident by looking at the tables, whereby values of the percentage compound remaining 
decrease from 100% over the 120 minute period. Used as a basis of control within the study, 
RMP exhibits a steady stable degradation within both concentrations of plasma. When RMP 
was incubated with 50% plasma, the degradation over 120 minutes was calculated to be a 
decrease of 15.9% overall since 84.1% of the compound was still remaining, and this stable 
degradation was also seen observed in a incubation of 100% plasma, where the percentage 
decrease now accounted for 17.6% since only 82.4% of the compound was present at the end. 
As mentioned previously, a stable compound provides for a better efficacy since the ADME 
process is much more balanced therefore the drug compounds can be absorbed steadily, 
distributed accordingly, metabolism slowly and then cleared quickly.  
Graphs showing the percentage of test compound remaining vs time for both concentrations 
of plasma used for incubation further stresses the stability of the internal control.  
 













Figure 36 Above; Plotted data curves to show the % of RMP remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing RMP and 100% Plasma concentration after an incubation period of 120 minutes. 
HPLC system was injected with an 80:20 MeOH/H20 ratio 
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3.3.1 Plasma Stability – DBM and Derivatives (Compounds 1-10) 
 
 
DBM has been stated to be a very stable compound till the 8h mark, however over a period 
of 120 minutes within this study, DBM was seen to degrade more than RMP. However, the 
concentration changes of plasma did not play a big role in the degradation since a percentage 
decrease of 30.8% was seen at 50% plasma compared to 37.7% within 100% plasma. This 
shows that the compound does not tend to undergo chemical changes such as hydrolysis or 
oxidation too much.  
As seen with the MTT cytotoxicity assay, the β-diketone derivatives of DBM also underwent 
compound degradation, with results such as instability and stability being observed.  
Candidates which contained the hydroxyl groups as part of their molecular substructure, 
Compounds 1,2, 3 and 5, all showed their ability to remain more stable than DBM in 50% 
plasma over a period of 120 minutes. Compound 2, which contained two hydroxyl groups was 
Figure 37 Plotted data curves to show the % of DBM remaining over the different incubation periods, when tested with 50% and 
100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15 
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the most stable out of all the derivatives, bringing into question the presence of more OH 
group, and the ability to form hydrogen bonds, since plasma contains water as a component. 
Compound 2, at a rate of 78.9% remaining, was followed by compound 1, which contained a 
sole hydroxyl group attached to the aromatic ring. This compound showed a 24.2% 
percentage decrease with 75.8% of compound available after degradation. Compounds 3 and 
5, both which have additional functional groups attached in addition to the Ortho contained 
hydroxyl groups displayed close values in terms of the assay, as both compounds had 73.5% 
and 73.1% test compound remaining after 120minutes, a decrease of 26.5% and 26.9%. 
However, when the test conditions were changed to the usage of 100% plasma, the same 
compounds experienced degradation at a much higher rate, values which were equal to that 
of DBM. These values, calculated as percentage compound remaining were as follows; 65.6% 
(1), 68.3% (2), 64.2% (3) and 63.4% (5). These values were compared to that of DBM at 62.3%. 
From the plots below (Fig 38-41), it can be deduced that the stability of the compounds within 
100% of plasma was much lower than that obtained from 50%. It was also noted that the 
compound, 2, which contained the most amount of hydroxyl groups, also experienced the 
most degradation. This maybe down to the effect of hydrolysis/oxidation taking place within 











Figure 38 Plotted data curves to show the % of Compound 1 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 1 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 







Figure 39 Plotted data curves to show the % of Compound 2 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 2 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 













Figure 40 Plotted data curves to show the % of Compound 3 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 3 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 





















Figure 41 Plotted data curves to show the % of Compound 5 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 5 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 
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Changing the group attached to the central carbon atom of the 1,3 diketone into a Br only 
showed a negative outcome, whereby the compound (4), was stable (68.7%) in 50% plasma, 
however rapidly degraded in 100% plasma (50.2%), a percentage decrease to be calculated 
at 49.8%. This further highlights the ability that a carbon, oxygen or nitrogen group attached 
to the central carbon can provide a stable effect. The rate the bromo contained compound 






















Figure 42 Plotted data curves to show the % of Compound 4 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 4 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 
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Other β-diketone derivatives tested for stability under the conditions, were the methoxy 
containing compounds, 6, 9 and 10. 
Compound 6 contains a simple methoxy group attached in the 4’ Para position of the aromatic, 
which is then symmetrical, therefore gives rise to a ‘Bis molecule. A CH3 group bond to the 
aromatic ring, with the help of an Oxygen, the methoxy group is classified as an ether, and is 
quite similar to an ester group. Ester’s have been known to undergo rapid hydrolysis thus 
rendering themselves as relatively unstable. Compound 6 however seems to contradict this 
theory and remains quite stable when incubated in 50% plasma (69.9%), a value not far from 
DBM (69.2%). However, a steady degradation is observed when the conditions change to full 
concentration of plasma, whereby the compound remaining has been reduced to 59.3%. 
Again, when compared to DBM (62.3%), this change in value is minimal and rapid hydrolysis 
is not observed here. The same steady change of time, under both conditions is seen with 
compounds 9 & 10, whereby methoxy groups were present as a group or on both rings. Both 
these compounds are much alike compound 6, where the percentage decrease in 50% plasma 
went from 37.2% and 37% to 43.8% for both within 100% plasma.  
When a fluorine group was added on the aromatic, with the methoxy groups still present, 
compounds 7 & 8 displayed the same activity as mentioned above, and a steady degradation 
of the compounds was observed in both 50% and 100% plasma conditions. The values 
calculated for both compounds in 50% plasma (64% and 63.9% remaining) and 100% (59.1% 
and 60.3%) was again relatively minimal in terms of rapid degradation.  







Figure 43 Plotted data curves to show the % of Compound 6 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. 








Figure 44 Plotted data curves to show the % of Compound 9 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 9 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 






Figure 45 Plotted data curves to show the % of Compound 10 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15 
Figure 46 Plotted data curves to show the % of Compound 7 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15 





Figure 47 Plotted data curves to show the % of Compound 8 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 8 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 
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The plots illustrated in Fig, 44-47 show the results where no rapid hydrolysis or compound 
degradation has taken place.  
3.3.2 Plasma Stability – 2-Azido Derivatives (Compounds 11 -13) 
Compounds 11,12 & 13 were synthesised with the option of allowing the β-diketone 
derivatives to contain a carbon, oxygen or nitrogen group at the central 1,3 diketone centre, 
in order to monitor the stability and efficacy of the bond. These nitrogen salt containing 
compounds should in theory provide a stable bond due to the ability of the nitrogen to openly 
bond, however this ideology has been proven wrong, since the data obtained shows the 
opposite effect taking place, ie compound instability. Table X shows the data values calculated 
for the percentage of compound which was remaining in 50% plasma, and all three 
compounds, 11,12 & 13 show a high level of instability where near less than half of the tested 
compound was remaining after 120 minutes. The values obtained 46.3% (11), 50.7% (12), 49.1% 
(13) were over 20% different from the compounds they were initially based upon in terms of 
substructure similarity (DBM, 1 and 3). Testing at 100% plasma, further rendered the use of 
the compounds negligible, since a rapid degradation trend was seen, whereby the 
compound/s remaining were less than 40%, this would show a percentage decrease of 60%. 
Compounds which contained some form of hydroxyl group, 12 (37.8%) and 13 (35.6) showed 
some stability in comparison to 11 (28.3%), which may not have lasted an assay of 4-8h of 
testing.  
 







Figure 48 Plotted data curves to show the % of Compound 11 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 11 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 








Figure 49 Plotted data curves to show the % of Compound 12 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 12 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 












Figure 50 Plotted data curves to show the % of Compound 13 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 13 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 
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The graphical plots further highlight the fact that the nitrogen salts did not favour the plasma 
conditions and may not provide the potential to be a future target compound. 
3.3.3 Plasma Stability – Benzoylurea Derivatives (Compounds 14 - 16) 
Benzoylurea’s, which in contrast to the β-diketone derivatives and azido salts are bulky 
molecules with respect to containing several different functional groups and bonds, displayed 
excellent stability in both plasma conditions, with values near the internal standard, RMP. It 
may be down to the different properties contained within the benzoylureas, or the presence 
of certain  bonds such as the amide (-NH) bond, all three compounds of this subclass, 14,15 
and 16 showed a loss of no more than 20%, with the following values being obtained; 82.3% 
(14), 80.1% (15) and 81.2% (16) in 50% plasma, which then decreased slightly to 79.3% (14), 
79.2 (15) and 80.3% (16) in 100% plasma. The minimal nominal changes experienced by the 
three compounds suggest that the bulkiness of the molecules, with the addition of different 
bonds, provides a platform for the compound to exhibit a higher level of stability within 
biological media. Due to this much required property, the ability of a drug to stay in the body 


















Figure 51 Plotted data curves to show the % of Compound 14 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 14 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 





















Figure 52 Plotted data curves to show the % of Compound 15 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 15 and 100% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 






Figure 53 Plotted data curves to show the % of Compound 16 remaining over the different incubation periods, when tested with 
50% and 100% Plasma concentrations. The graphs have been plotted using data from Table 14 & 15. Below; HPLC spectra 
obtained after running a sample containing Compound 16 and 50% Plasma concentration at incubation period 120 min. HPLC 
system was injected with an 80:20 MeOH/H20 ratio 
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Figs 51-53 plots showing the relative stability of all three benzoylurea compounds  
It should be noted that the tested compounds, be it the active drug or their metabolites may 
at the time of testing not be relative to their initial concentration measured. This correlates 
with the fact that optimal conditions for the compounds in question are not maintained in 
terms of handling, storing or even processing the samples prior to their analysis and testing 
as mentioned by Reid., (2016). Due to this, the results obtained may not accurately reflect the 
concentration of the compound in the sample to when it was acquired prior to the testing 
phase. Since this may be the case, the analytes maybe unstable under the conditions they 
were exposed to, thus leading to an earlier and quicker degradation. The same can be said for 
the biological medium such as serum and plasma in addition to the compounds which were 
tested. Leading on this can be a factor within this study, since the plasma which was initially 
stored at -200C, was then thawed at room temperature and then frozen again. It has been 
suggested that in these circumstances where samples are thawed and stored, that the 
stability testing be run multiple times over freeze/thaw cycles. Toseland et al., (2010) advice 
that the best storage for the temperature of most drugs is at 4°C for short‐term storage and 
at –20°C for long‐term storage. However, it should be considered that even though freezing 
and decreasing the temperature slows down both the rate of metabolic and chemical 
degradation, it does not absolutely stop those processes from occurring. Previous studies 
have reported the potential findings with regards to the stability of drugs in vitro. El Mahjob 
et al (56) observed that the drugs Midazolam, Oxazepam, Clonazepam amongst others were 
found to be stable for a period of 1 year when optimal conditions were utilised such as storage 
at −80 °C. When compounds were stored at a lower temperature (−20 °C), there was losses 
of 5% and 20% found for the high and low concentrations respectively. This further followed 
by the storage condition increasing in temperature to 4 °C, whereby the effect of refrigeration 
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caused a decrease in concentration of 50% for the high dose concentration and more than 
90% for the low concentration. Finally, when the study was conducted on compounds stored 
at RT, the losses at low concentration for all drugs were at 100% and 70% for the high 
concentration. This links to the β-diketone derivatives, where changes in temperature effect 
the equilibrium balance of the keto-enol tautermor. A change in the structure or bond 
between the functional group can cause different activity responses to be generated, which 
may have a fundamental effect on the assays, since a C=C double bond of the alkene is much 
less reactive due to electronegativity when compared with that of a C=O bond from the 
carbonyl. Both these forms are in equilibrium as discussed previously.  
To try and overcome the effect of prolonged exposure whilst preparation steps are taking 
place, a traditional idea has been suggested by Clapton et al., (2017), with two different 
approaches that can be utilised. The first approach is to start the incubation period of each 
sample in the buffer at a different time right before the time of injection, whereas the second 
approach suggests that all the samples are frozen immediately after the reaction at -800C in 
order to stop the reaction from progressing. The samples will then be thawed on a one by 
one basis right before analysis, thus decreasing the exposure time.  
Hydrolysis, a process when a compound is split in two, or the breakdown of a compound when 
it reacts with water and oxidation, a reaction whereby the transfer/loss of electrons and 
possible addition of oxygen has taken place. has taken place, are two of the prime mechanism 
by how a compound will degrade in plasma. Since plasma mainly contains water, hydrolysis 
will therefore be the main process. As mentioned before, contained within the group which 
a susceptible to hydrolysis is amides. Synthesised as part of this study were a series of 
Benzoylurea derivatives, which contain a central urea amine linkage, neighboured by a 
carbonyl group (C=O) and a carbonothioyl (C=S) group. Accordingly, the hydrolysis mechanism 
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on an amide group has a very high potential to produce a carboxylic acid (-COOH) and an 
amine (-NH2).  
 
From a medicinal chemistry point of view, different functional group provide specific chemical 
properties and exhibit certain behaviours which further allow a drug molecule to exert its 
desired effect, both in terms of pharmacokinetics and pharmacodynamics. The is a big list of 
parameters in which a drug compound can play a significant role with regards to response, 
and the list includes factors such as water/lipid solubility, mechanism of action, route of 
metabolism and elimination and the ability to interact with biological targets. Due to the 
difference in the roles played by functional groups, some are classified as more significant 
than others. Since most drugs are small organic molecules, the only difference between them 
would be the type of functional groups present and the connectivity between these groups. 
This further allows for the possibility to alter functional group in order to better the activity, 
increase absorption, decrease potential side effect or in the long term, provide a better course 
of action for an alternative therapeutic effect. 
When a single function group is added to a specific molecule, wholesome changes will and 
can occur. This means affecting the overall balance of the molecule in terms of solubility and 
steric dimensions. An example of this will be the addition of a para hydroxyl group to an 
aromatic system, which potentially will influence the electron density of the aromatic ring 
through its ability to interact with the electrons present. The hydroxyl group has been a 
functional group which can affect the dynamics of a compound, since the focal addition of the 
-OH group will help to increase the water solubility of the compound, whereby the possibility 
of forming hydrogen bonds will increase significantly, and especially in plasma, since water 
makes up around 90% of it. As well as the ability to form hydrogen bonds, since the hydroxyl 
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group is off a larger size than the original hydrogen atom it replaced, the overall steric 
dimension of the compound is also affected. Another benefit of replacing a functional group 
with a hydroxyl, or even an aromatic amine, aromatic thiol or simple methoxy group is that 
these groups contain functional groups with lone pair, which are readily donated into the 
phenyl or aromatic ring system. Functional group substitution was observed during the 
synthesis of the β-diketones, where to the common DBM structure, functional groups such as 
hydroxyl, methoxy and halogens were added. This was in order to see if either these 
substitutions made significant effects on the compound with regards to plasma stability and 
degradation. As observed from the results, it was seen that the addition of hydroxyl groups 
provided a stable compound than the original DBM, however replacing with methoxy was not 
as successful. Oddly, the derivatives which contained the urea and amide groups exhibited a 
better stability in plasma than the β-diketones, especially since the hydrolysis of amides is 
common. However, since the compound contained a bulky structure with other functional 
groups present as a means of shielding, the compounds may have degraded in the long run. 
The idea here is of steric hindrance, a very common strategy which is used to block or slow a 
specific metabolic pathway. By using this approach, additional atoms are added adjacent to 
functional groups undergoing the metabolism in order to block the interaction of the drug 
molecule with the enzyme. Another reasonable explanation for the ability of Benzoylurea 
derivatives to be more stable than the 2-Azido-diketones or β-diketones would be the 
presence of the di-carbonyl functional groups instead of the one. Since oxygen can draw 
electrons towards itself much more efficient and strongly than carbon, the C=O becomes 
polarised, leaving the oxygen with a negative charge and in turn, the carbon with a positive 
charge. Due to the rise of this polarisation, the electrons on the oxygen of a water molecule 
are attracted to the slightly positive charge of the carbon atom, thus resulting in the process 
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of hydrolysis. This hydrolysis reaction is known to proceed more rapidly with esters than 
amides, and this would be the case where methoxy functional groups bonded to oxygen as 
an ether were shown to be less stable than DBM or any other hydroxyl containing compound. 
The reason for the difference in the rates of hydrolysis is down to the difference in structural 
differences between the two functional groups. The ester contains an oxygen atom, whereas 
the amide is attached to a nitrogen atom at the same position, and this difference brings in 
the ability of charge and attraction. As the carbonyl group is much more positively charged 
than that of the amide, this leads to a greater attraction between the carbon and water. 
Nitrogen on the other hand lessens that positive charge in the carbonyl atom, thus present 
less of an attraction to incoming water molecules, an observation made in the plasma stability 
assay, where the most stable compounds were the amide containing Benzoylurea derivatives. 
The same can be said for the 2-Azido-diketones, which even though contain an imine 
functional group, are said to degrade rapidly, a finding which was observed here. A finding by 
sheikh et al shows the structurally similar compound Curcumin to contain two phenolic 
hydroxyl groups, which when ionized causes a destabilization effect on curcumin, leading it 
towards oxidation and hydrolysis. Furthermore, it has been found that Curcumin is also very 
potent in cancer chemoprevention, but its plasma concentrations were found to be very low 
in rodents and human after oral administration probably due to low bioavailability (Jackson 
et al., 2002).  Therefore, for further clinical application, the dietary chemopreventive 
compounds require more knowledge of in vivo pharmacokinetics including absorption, 
distribution, metabolism and excretion. 
 
 
166 | P a g e  
 
3.2.4  S9 Fraction Stability 
 
Plenty of in vitro studies predominantly work on focussing their attention towards using 
compounds such as hepatocytes or specific subcellular hepatic fractions like S9 as in study 
reagents. More commonly these useful in vitro models are being used as a means of hepatic 
clearance as they contain many and various drug metabolising enzymes. One was mentioned 
above, the S9 fraction, with the other vital one being microsomes. These products of organ 
tissue homogenates are widely used in many biological assays thus the incubation of potential 
drug candidates with the addition of the S9 fraction can aid to help understand the metabolic 
fate of the compound in question or testing. This further provides a major advantage to using 
S9 fractions, which is a crude cell preparation, as in addition to containing a variety of Phase 
I and Phase II metabolising enzymes, the subcellular fractions are also sufficiently easy to 
prepare, use and store, for long periods of time, enabling cost efficiencies over whole cell 
models. Adding onto the advantages mentioned, the final point is that the subcellular 
fractions are said to be easily adaptable to high throughput screens, which then enables a 
huge number of compounds to be screened, at a rapid pace and inexpensive cost. 
An important factor is that they contain both cytosolic enzymes like sulfotransferases, 
aldehyde oxidase and membrane-bound enzymes such as CYP450 (Varkhede et al, 2014). The 
cytosol part contains transferases, which are Phase II enzymes. The function of these is to 
transfer a functional group such as Hydroxyl or amine from one molecule to another. The 
microsomes part contain the Cytochrome P450, which is a Phase I metabolite. These are a 
group of hemoproteins, which are involved in drug metabolism itself, accounting for 
approximately ¾ of the total metabolism. The function is conducted when the heam group 
conducts oxidation on the substrates present. This is done by using protons derived for the 
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NADH or NADPH substances, which act as co-factors to the S9, to split the oxygen present so 
that a single atom can be added to the substrate of the enzymes. Many drugs currently on 
the market today undergo their biotransformation via oxidations.  
Subcellular fractions are mostly conducted using animals in order to estimate the risk of 
specific compounds causing cancer in humans, with the most common species used being 
Rattus norvegicus (Rat) and Mus musculus (Mouse). Prival and Mitchell, 1982, Lijinsky and 
Andrews, 1983, Nohmi et al., 1983 and Le et al., 1985 all mention that the usage of these 
subcellular fractions, combined with or without enzymes, are considered very useful in the 
screening of mutagens from the viewpoints of their susceptibility to promutagens. This is 
further agreed by Maron and Ames (1983), Mortelmans and Zeiger (2000) who add that the 
effectiveness of the S9 fractions are because they effectively bioactivate the promutagens 
into mutagens, thus enabling them to be sufficiently good in mutagenicity screening test 
systems. 
 
The S9 incubation assay helps to provide an understanding for the metabolism of compounds, 
in turn helping to predict pharmacological data such as in vitro intrinsic clearance, the intrinsic 
capability of the eliminating organ to remove the free drug from the body (Cl’int). 
Furthermore, calculation could be made to determine the half-life of the compounds testing, 
with a view to see how the body eliminates such substances and how often. Like the plasma 
stability, RMP was used as an internal control, and all work was carried out in triplicate. 
However, since a known compound which is unstable within these conditions was not used 
as a positive control, the data is presented within a preliminary stage of the study 
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All the compounds were tested via this S9 fraction assay to determine their metabolic stability 
in order to calculate half-life (t1/2) and Intrinsic Clearance (CTint), the amount of compound 
cleared/removed within a minute. Different time intervals were measured up until the 45-
minute mark, with the natural log (ln) of the Percentage test compound remaining plotted 
against time. The former would then allow for a gradient to be calculated from the line, which 
would then help to determine the t1/2 and following this, the CTint, measured in µL/min/mg 
protein. The following formulae were utilised to help with the calculations. 
 
Elimination rate constant (k) = (gradient) 
Half Life (t1/2) (min) = 0.693/k 
V (µL/mg) = volume of incubation (µL) / protein in the incubation (mg) 
Intrinsic Clearance (CLint)(µL/min mg protein) = V x 0.693 / t1/2 
 
A scoring guide was used to consider whether the CTint value calculated was either expressed 
as high or low in terms of human metabolism on the tested compound. The scale used for the 
analysis of the results is as follows; 
Low < 4.5 
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Table 16 Data values for all compounds calculating pharmacokinetic parameters such as 
Half life (t1/2) in minutes, Intrinsic Clearance and the overall % decrease of the starting 
compound tested with the S9 Fraction contained after an incubation period of 0-45 minutes.  
Compound Half Life (t1/2)/min CTint  (µL/min/mg 
protein) 
% decrease from 
time 0 to 45 (min) 
RMP 29.48 ± 2.3138 
 
12.0085 ± 0.6914 66.3 ± 0.69 
DBM 27.94 ± 1.7174 
 
12.6728 ± 0.7667 68.7 ± 0.36 
1 21.93 ± 1.7258 
 
16.1476 ± 0.8539 77.2 ± 0.71 
2 21.06 ± 1.8257 
 
16.8119 ± 0.6111 79..0 ± 0.63 
3 24.40 ± 2.3944 
 
14.5124 ± 0.4352 74.7 ± 0.45 
4 34.13 ± 2.6669 
 
10.3733 ± 0.8434 60.8 ± 0.36 
5 28.40 ± 2.166 
 
12.4684 ± 0.9417 68.1 ± 0.21 
6 31.93 ± 2.101 
 
11.0887 ± 0.3519 65.3 ± 0.95 
7 41.49 ± 1.6428 
 
8.5337 ± 0.2195 54.0 ± 0.61 
8 44.42 ± 2.1007 7.9716 ± 0.6514 51.5 ± 0.84 
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9 37.86 ± 2.0188 
 
9.3513 ± 0.7365 55.9 ± 0.71 
10 36.09 ± 1.9816 
 
9.8112 ± 0.3657 59.4 ± 0.26 
11 15.50 ± 1.3018 
 
22.8417 ± 0.1265 88.5 ± 0.23 
12 14.68 ± 1.4368 
 
24.1192 ± 0.4598 89.7 ± 0.56 
13 16.04 ± 1.5205 
 
22.0752 ± 0.3697 88.0 ± 0.19 
14 147.44 ± 1.4767 
 
2.4017 ± 0.2825 20.1 ± 0.54 
15 128.33 ± 2.0071 
 
2.7594 ± 0.4629 21.7 ± 0.66 
16 133.26 ± 1.2490 
 
2.6572 ± 0.5624 20.4 ± 0.15 
 
 
From the Table 16, it is evident that all the compounds which were synthesised, β-diketones, 
2-Azido-diketones and the Benzoylurea derivatives, all have intrinsic clearance whereby the 
values fall into the upper and lower ranges. The highest value found was just short of the scale 
used at 24.1192 µL/min/mg protein however the lowest values calculated were under that of 
4.5, averaging 2.6061 µL/min/mg protein. 
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RMP was calculated to have a CTint value of 12.0085, a value which falls between the halfway 
stage of 4.5 and 24.6. The same observations can be made with the β-diketone derivatives 
including DBM, where the values range from between a low of 7.97 to a high of 16.81. From 
the calculated values within the table, it has been observed that compounds 1,2,3 & 5, all 
which contain the hydroxyl groups have a higher clearance value. This was the case with both 
the β-diketones and the 2-Azido-diketones. The following observation was then linked to a 
correlation regarding t1/2, through which it was seen that a candidate with a shorter half life 
had a high CTint. 
An example of this would be compound 1 and 12. Here a mono hydroxyl group is present on 
the β-diketone and the similar 2-Azido-diketone structure. The t1/2 of 1 was shown to be 21.93 
min and off 12 to be 14.68 min. The CTint values calculated were 16.1476 and 24.1192. This 
proves the theory above to be correct.  
3.2.4.1 S9 Fraction Stability – DBM And Derivatives (Compounds 1 – 10) 
Nearly all β-diketone derivatives displayed calculated values of both t1/2 and CTint to be close 
to RMP, the internal control, however compounds which contained much bulkier functional 
groups such as compounds 7,8,9 & 10, where methoxy substituents amongst others were 
present, displayed a slightly higher half life and lower CTint. Compounds 7 and 8, which 
contained the Fluorine group, had a t1/2 calculated of 41.49 and 44.42 in comparison to 29.48 
of RMP and 27.94 of DBM. The CTint values calculated also differed by approx. 66%, with 
8.5337 (7) and 7.9716 (8) being calculated in contrast to 12.0085 (RMP) and 12.6728 (DBM). 
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Figure 54 Plotted data curves to show the % of Compound RMP (left) and DBM (right) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing RMP 
and S9 Fraction at time intervals of 10 min and 45 min respectively. HPLC system was injected with an 80:20 MeOH/H20 ratio 















Figure 55 Plotted data curves to show the % of Compound 1 (a) and Compound 2 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 1 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 
 















Figure 56 Plotted data curves to show the % of Compound 3 (a) and Compound 4 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 4 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 ratio 






Figure 57 Plotted data curves to show the % of Compound 5 (a) and Compound 6 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 5 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 ratio 





Figure 58 Plotted data curves to show the % of Compound 9 (a) and Compound 10 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 9 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 







Figure 59 Plotted data curves to show the % of Compound 7 (a) and Compound 8 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 7 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 
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3.2.4.2 S9 Fraction Stability – 2-Azido and Benzoylurea Derivatives (Compounds 11 – 16) 
The plots in Fig 60-62 displayed the percentage of test compound which was remaining after 
the 45-minute incubation period with the S9 fraction. The overall percentage decrease value 
for each compound from T0 to T45 can be collected from table 16 
 
Following further screening on the remainder of the derivatives, a major difference was found 
between the class of 2-Azido-diketones and Benzoylurea derivatives with regards to their 
stability in plasma. All three 2-Azido derivatives, 11,12 & 13, had relatively short t1/2 half life 
values of under 15 minutes, with CTint values above 22.00. This finding therefore rendered the 
2-Azido class of compounds as relatively instable and prone to a high level of metabolism by 
the biological enzymes, in comparison to the Benzoylurea derivatives, which displayed half 
life values of over 125 minutes, with very low CTint values calculated such as 2.7594, 2.6572 
and 2.4017 respectively. These values were regarded as low, if compared to the ranking scale 
used by Cyprotex. The increased metabolic stability can be down to the different types of 
functional groups and bonds present in the structure of the Benzoylurea derivatives when 
compared to the simple skeletal structures of both β-diketones and 2-Azido-diketone 
derivatives.  When both the class of compounds are compared to the internal control, it can 
be deduced that the 2-Azido-diketones are less stable than RMP but on the other hand, the 
Benzoylurea derivatives are more stable.  





Figure 60 Plotted data curves to show the % of Compound 11 (a) and Compound 12 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 12 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 





Figure 61 Plotted data curves to show the % of Compound 13 (a) and Compound 14 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 13 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 





Figure 62 Plotted data curves to show the % of Compound 15 (a) and Compound 16 (b) remaining over the different incubation 
periods, when tested in the presence of the S9 Fraction. Below; HPLC spectra obtained after running a sample containing 
Compound 15 and S9 Fraction after an incubation period of 45 minutes. HPLC system was injected with an 80:20 MeOH/H20 
ratio 
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The plots above shows the difference in the percentage compound remain for both the 2-
Azido-diketone compounds and the Benzoylurea compounds. The ability of the benzoylurea 
compounds to be more stable is highlighted. 
The role of ADME studies in drug discovery is critical in order to optimize the drug like 
properties exhibited by NCE thus helping to increase their level of success in the later stages 
of the drug discovery process. By using the concepts of in vitro metabolic stability, it allows 
for the prediction of clearance made from the body by the liver. By doing this allows for a 
greater understanding in prioritising the progression of a compound which exhibits and 
displays potentially favour results (Hartman., 2003). Earlier studies published have since 
suggested that the intrinsic clearance obtained from in vitro metabolic studies can be used 
with the principal of predicting in vivo clearance. From the S9 fraction stability assay, the main 
concept is to obtain a compound which achieves low clearance, which in turn helps to reduce 
the does, enhance the exposure of the compound and prolong half-life. However, the ability 
of finding a low clearance compound through in vitro liver microsomal or hepatocyte assays 
is a big challenge since many low clearance compounds fail in clinic due to extremely long 
half-lives. This is because the liver is a primary site of metabolism, and like with every new 
tested drug, the drug metabolic transformations may have a significant impact on its safety 
and efficacy to clear and eliminate from the body. Due to this reason alone, the use of 
microsomes from either human or animal liver provide the platform to be used as useful 
models, which allow for the quick and inexpensive projection of hepatic clearance. Li Di et al 
(2015) mentions that a rapid and comprehensive metabolic stability serves as an effective 
gate in eliminating low value compounds. As mentioned above, the microsomes provide an 
inexpensive model to be used, however the enzymatic set up is limited to which is only 
contained in the endoplasmic reticulum. This means that the biological model only contains 
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Phase I enzymes and results will only allow for the information based on this. In contrast to 
this, the S9 liver fraction contains both phase I and II metabolic enzymes, which makes them 
more favourable and easier to use. This is also because the fractions are very easily obtained 
during the early stages of liver microsomal preparation but in addition contain both 
microsomal and cytosolic fractions that provide more metabolic information than 
microsomes alone. Contained as cytosolic fractions are the enzymes aldehydes oxidase, 
xanthine oxidase, sulfotransferases, methyltransferases, N-acetyl transferases and finally 
glutathione transferases, which have recently gained appreciation as a major contributor for 
the metabolism of certain chemotypes. Samantha et al further state that the fraction also 
contains phase I oxidative, reductive and hydrolytic enzymes, and as seen in the previous 
assay for the synthesised compounds, they are susceptible to hydrolysis, except the 
Benzoylurea derivatives. Since the S9 fraction contains CYP enzymes, particularly CYP1A2, 
CYP2C9, CYP2C19, CYP2D6 AND CYP3A4, these are responsible for the bulk of the metabolism 
of drugs in humans and are known for approximately 80% of oxidative drug metabolism. Since 
a relatively low number of studies have been published on the synthesised compounds and 
the assays conducted, judgements can be made on similar structures which have been studied 
intensively. DBM is said to be structurally similar to that of Curcumin, as mentioned previous, 
and studies shown for Curcumin highlight the fact that it has an unfavourable 
pharmacokinetic profile consisting of poor absorption, a quick rapid metabolism which render 
it as unstable, and following on, a rapid elimination, which leads to a short plasma half-life 
and low concentrations in target tissues. This may be down to the fact that cell uptake plays 
a rate-limiting role in metabolic clearance and research has shown the membrane 
permeability may limit the uptake of a compound and therefore its ability to reach the target. 
This would be possible when a high permeability compound can display slow intrinsic 
185 | P a g e  
 
clearance due to the fact it has a slow metabolic turnover after a rapid uptake initially. In 
order to overcome this barrier, assays such as octonol/water partitioning may be used as a 
model to see the hydrophilicity and lipophilicity of certain compounds. From the LogD values, 
it can be predicted how much of the compound will cross the membrane barrier. Moving on, 
it has been stated that compounds with half-lives under 30 minutes were binned as unstable 
in comparison to those with a half-life over 30 minutes, which were labelled as stable. From 
the results obtained and calculated it would be suggested that the Benzoylurea derivatives 
can be labelled as unstable due to a half-life of over 30 minutes and an intrinsic clearance of 
under 2.5, followed by the β-diketones derivatives which contained the hydroxyl groups. If 
the half life values are to be considered, then the hydroxyl containing compounds, including 
DBM and the 2-Azido-diketone would also fall under the unstable category. The compounds 
which were degraded quick within plasma, since they contained methoxy functional groups 
are deemed as the most stable, since they all have a half-life better than 30 minutes but also 
average intrinsic clearance values of around 10 µL/min/mg protein.  
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Figure 63 Graphical illustration/s plotted to show the Intrinsic Clearance for each compound tested in the presence of S9 Fraction.  
Graphs were plotted using data from Table 16 and show the following compounds respectively; a). RMP, DBM and derivatives b). 
RMP and the 2-Azido derivatives c) RMP and the Benzoylurea derivatives 
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3.3 Conclusion and Future Work 
 
In conclusion, based on the experimental studies conducted, it can be said that some 
synthesised compounds have shown more potential anti-cancer activity than other 
derivatives. However, no derivative showed great potential in each study completely as it was 
seen that if there was bias for a compound to show potential in a biological assay, then the 
same compound lacked that potential within the pharmacological assay. Overall, across all 
studies, the DBM and the diketone derivatives containing the OH hydroxyl groups performed 
much better in terms of cytotoxicity and stability than seen from the other compounds. This 
somewhat supports the theory that a compound does not need to be bulky in order to get 
the required response rather contain Functional groups which have an impact and cause 
activity. However, on the other hand, the much bulkier Benzoylurea derivatives showed good 
stability within the plasma stability assays but a low intrinsic clearance when subjected to the 
S9 Fraction. Furthermore, it should be noted that the 2-Azido derivatives did not show 
potential in both cytotoxicity and stability, and when going forward should either be 
disregarded or altered to enhance activity.  
Going forward, the compounds need to be tested under much stricter conditions and utilising 
the correct controls, ie positive and negative. Once a full set of data is obtained within the 
studies such as the Plasma Stability and S9 Fraction stability assays, then further biological 
and pharmacological work can be carried out. These tests can include putting the compounds 
through flow cytometry, in order to see which phase/s of the cell cycle the compounds have 
activity in, thus rendering them cell cycle specific, determining the LogD value which 
highlights the ability to pass different barriers such as lipids. Furthermore, different genes can 
be tested via DNA/RNA extraction to see if the candidates respond to different gene 
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expression. In addition, there is further scope for the candidates to react with metals, mainly 
transition, to form metal complexes. By doing this, this may alter the structure of the 
compound and further enhance activity in order to get the required response that is needed 
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